Tag Archives: CELG

Top 10 Performing Stocks To Invest In 2021

On Wednesday, our Elite Opportunity Pro newsletter suggested a speculative entry into small cap Actionable Intelligence solutions stock Verint Systems (NASDAQ: VRNT):

“Today’s new idea is one of those potential takeout candidates considering the need for large and mega-caps to continue growing their top and bottom lines via acquisition, and there’s clearly been plenty of that going on these days. Not only does Verint Systems Inc. (VRNT) offer potential value around current levels, just yesterday the stock moved sharply higher on abnormally high volume. And, the technical event came on no news or looming rumors…”

“….Technically, I’ve included tow charts of the stock below, a weekly and a daily. As you can see on the weekly chart here, although VRNT has definitely seen better days, you can also see the stock has continued to build a base for several months now. Additionally, when you drill down into the daily chart, you can see the stock just recently retraced 5/8th’s of a pretty nice move, and then just yesterday moved sharply higher on what appears to be some pretty large fund buying.”

Top 10 Performing Stocks To Invest In 2021: Sypris Solutions Inc.(SYPR)

Sypris Solutions, Inc. provides of outsourced services and specialty products primarily in North America and Mexico. It offers a range of manufacturing, engineering, design, and other technical services under contracts with corporations and government agencies primarily in industrial manufacturing, and aerospace and defense electronics markets. The company supplies forged and machined components to the commercial vehicle, off highway vehicle, light truck, and energy markets, as well as produces drive train components, such as axle shafts, gear sets, differential cases, steer axle forgings, and other components. It also provides solutions in cyber security, secure communications, global electronic key management, Sypris Data Systems branded products, and product design and development to the United States Government, defense and civilian agencies, international government agencies, as well as worldwide defense and aerospace prime organizations. In addition, the company desi gns and builds information assurance products, including link encryptors, data recording products, and electronic key fill devices. Further, it offers electronic manufacturing services, including circuit card and full box build manufacturing; dedicated space and high reliability manufacturing; integrated design and engineering services; systems assembly and integration design for manufacturability; and design to specification works. The company was founded in 1954 and is based in Louisville, Kentucky.

Advisors’ Opinion:

  • [By Lisa Levin]

    Sypris Solutions, Inc. (NASDAQ: SYPR) is projected to report quarterly loss at $0.07 per share on revenue of $20.35 million.

    Fusion Connect, Inc. (NASDAQ: FSNN) is expected to report quarterly loss at $0.11 per share on revenue of $36.71 million.

Top 10 Performing Stocks To Invest In 2021: Humana Inc.(HUM)

Humana Inc. offers various health and supplemental benefit plans in the United States. Its Government segment consists of beneficiaries of government benefit programs; and operates in three lines of businesses, including Medicare, Military, and Medicaid. The Medicare program provides hospital and medical insurance benefits to persons of age 65 and over and some disabled persons under the age of 65. The Military program offers health insurance coverage to the dependents of duty military personnel, and to retired military personnel and their dependents. The Medicaid program is a federal program that is state-operated to facilitate the delivery of health care services primarily to low-income residents. The Commercial segment consists of members enrolled in its medical and specialty products marketed to employer groups and individuals. This segment provides health maintenance organization products that offer prepaid health insurance coverage to its members through a network of independent primary care physicians, specialty physicians, and other health care providers; preferred provider organization products, which are offered primarily to employer groups and individuals; and administrative services only products that are provided to employers who self-insure their employee health plans. It also offers various specialty products, including dental, vision, and other supplemental products, as well as disease management services. As of December 31, 2010, Humana Inc. had approximately 10.2 million members enrolled in medical benefit plans; and approximately 7.1 million members enrolled in specialty products programs. The company markets its products through various channels comprising television, radio, the Internet, telemarketing, and direct mailings. In addition, it has strategic alliances with Wal-Mart Stores, Inc.; State Farm; and United Services Automobile Association to market its products. The company was founded in 1961 and is headquartered in Louisville, Kentucky.

Advisors’ Opinion:

  • [By Joseph Griffin]

    Traders bought shares of Humana Inc (NYSE:HUM) on weakness during trading hours on Monday. $146.79 million flowed into the stock on the tick-up and $70.85 million flowed out of the stock on the tick-down, for a money net flow of $75.94 million into the stock. Of all stocks tracked, Humana had the 6th highest net in-flow for the day. Humana traded down ($4.81) for the day and closed at $304.87

  • [By Ethan Ryder]

    Humana Inc (NYSE:HUM) – Piper Jaffray Companies upped their Q3 2019 EPS estimates for Humana in a note issued to investors on Sunday, September 30th. Piper Jaffray Companies analyst S. James now anticipates that the insurance provider will post earnings of $4.86 per share for the quarter, up from their previous estimate of $4.74. Piper Jaffray Companies has a “Overweight” rating and a $380.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Humana’s Q4 2019 earnings at $3.51 EPS.

  • [By Stephan Byrd]

    Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 1st. The insurance provider reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.17. Humana had a return on equity of 17.43% and a net margin of 2.48%. The business had revenue of $14.26 billion during the quarter, compared to analysts’ expectations of $14.16 billion. During the same quarter last year, the company posted $3.49 earnings per share. sell-side analysts predict that Humana Inc will post 14.18 EPS for the current year.

Top 10 Performing Stocks To Invest In 2021: Ryman Hospitality Properties, Inc.(RHP)

Ryman Hospitality Properties, Inc., incorporated on June 21, 2012, is a self-advised and self-administered real estate investment trust (REIT). The Company focuses on group-oriented, destination hotel assets in urban and resort markets. The Company’s segments include Hospitality, which includes its hotel properties and the results of hotel operations; Entertainment, which includes its Grand Ole Opry assets, WSM-AM and its Nashville assets, and Corporate and Other, which includes corporate expenses. Its assets include a network of approximately four upscale, meetings-focused resorts totaling over 7,790 rooms that are managed by lodging operator Marriott International, Inc. (Marriott) under the Gaylord Hotels brand.

Hospitality

The Company’s Hospitality segment consists of Gaylord Opryland, which comprises Gaylord Opryland Resort & Convention Center in Nashville, Tennessee; Gaylord National, which comprises the Gaylord National Resort & Convention Center near Washington, District of Columbia ;Gaylord Palms, which comprises the Gaylord Palms Resort & Convention Center near Orlando, Florida; Gaylord Texan, which comprises the Gaylord Texan Resort & Convention Center near Dallas, Texas; Inn at Opryland, and the AC Hotel. The Company owns its Opryland complex in Nashville, Tennessee, which includes the site of Gaylord Opryland of approximately 170. It also owns the six-acre site of the Inn at Opryland, which is located near the Opryland complex and has over 300 rooms. It has leased a 65-acre tract in Osceola County, Florida, on which the Gaylord Palms is located. It holds over 80 acres in Grapevine, Texas, through ownership of approximately 70 acres and ground lease of approximately 10 acres, on which the Gaylord Texan is located. It also owns an additional of over 20 acres of property adjacent to the Gaylord Texan. It owns approximately 40 acres on the Potomac River in Prince George’s County, Maryland, on which the Gaylord National is located. The Gaylord Opryland has over 2,880 s! ignature guest rooms, approximately four ballrooms with approximately 127,000 square feet, over 110 banquet/meeting rooms, and total meeting, exhibit and pre-function space of approximately 640,000 square feet.

Entertainment

The Company owns the General Jackson’s docking facility, the Grand Ole Opry House and WSM Radio’s offices and studios, each of which are located within the Opryland complex. It also owns Gaylord Springs, an 18-hole golf course situated on over 200 acres, which is located near the Opryland complex. In downtown Nashville, it owns the Ryman Auditorium and the Wildhorse Saloon dance hall and production facility. Its taxable REIT subsidiaries’ (TRSs) lessees have engaged Marriott to manage the day-to-day operations of the General Jackson Showboat, Gaylord Springs and the Wildhorse Saloon.

Advisors’ Opinion:

  • [By Max Byerly]

    Ryman Hospitality Properties Inc (NYSE:RHP) CEO Colin V. Reed purchased 6,106 shares of the business’s stock in a transaction on Monday, March 4th. The stock was bought at an average cost of $82.46 per share, for a total transaction of $503,500.76. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

  • [By Motley Fool Transcribers]

    Ryman Hospitality Properties Inc  (NYSE:RHP)Q4 2018 Earnings Conference CallFeb. 26, 2019, 11:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 10 Performing Stocks To Invest In 2021: Kimco Realty Corporation(KIM)

Kimco Realty Corporation, incorporated on March 25, 1994, is a real estate investment trust. The Company is engaged principally in the ownership, management, development and operation of open-air shopping centers. The Company holds interests in approximately 610 shopping center properties, aggregating over 100 million square feet of gross leasable area (GLA), located in approximately 40 states of the United States, Puerto Rico and Canada.

The Company holds approximately 450 other property interests, primarily through the Company’s preferred equity investments and other real estate investments, totaling over 7.3 million square feet of GLA. The Company’s shopping centers are anchored generally by discount department stores, supermarkets or drugstores. The Company’s shopping center properties have various national and regional companies as tenants, such as TJX Companies, The Home Depot, Bed Bath & Beyond, Royal Ahold, Albertsons, Wal-Mart, Kohl’s, Petsmart and Ross Stores.

Advisors’ Opinion:

  • [By ]

    Unlike the group above, Kimco Realty Corporation (NYSE: KIM) is a shopping mall real estate investment trust (REIT) trading far below its all-time highs. But it still looks expensive. While its open-air shopping malls are located mostly in the top metropolitan markets — and mostly from grocery-anchored centers at that — it’s fighting a long-term e-commerce trend. Kimco may be an income stock, but this does not mean that it won’t decline if its results disappoint or if the market deteriorates. I would be careful with KIM at this time. 

  • [By Reuben Gregg Brewer]

    Real estate investment trust (REIT) Kimco Realty (NYSE:KIM) owns retail properties. With the retail industry in a state of flux, often referred to with the hyperbolic term “the retail apocalypse,” investors haven’t been too keen on the company’s shares of late. In fact, the shares are 45% off of the highs reached in mid-2016, and the yield is over 6%, higher than it has been since 2011 despite annual dividend hikes since that date. For those who can see past the retail apocalypse hype, though, Kimco is worth a deep dive.

  • [By Reuben Gregg Brewer]

    But that’s not the full story, either. Kimco Realty (NYSE:KIM), one of the nation’s largest shopping-center owners, lost around 19% in 2018, yet it outdistanced the S&P and the REIT average in January with a 16% gain. That’s roughly 6 percentage points better than Retail Opportunity Investments did. Why?

  • [By Stephan Byrd]

    Worldquant Millennium Quantitative Strategies LLC bought a new stake in Kimco Realty Corp (NYSE:KIM) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 85,388 shares of the real estate investment trust’s stock, valued at approximately $1,451,000.

Top 10 Performing Stocks To Invest In 2021: Bonanza Creek Energy, Inc.(BCEI)

Bonanza Creek Energy Inc., an independent energy company, engages in the acquisition, exploration, development, and production of onshore oil and associated liquids-rich natural gas in the United States. The company’s oil and liquids weighted assets are located primarily in the Wattenberg Field in Colorado; and the Dorcheat Macedonia Field in southern Arkansas. It also owns and operates oil-producing assets in the North Park Basin in Colorado; and the McKamie Patton Field in Southern Arkansas. Bonanza Creek Energy Inc. was founded in 2010 and is headquartered in Denver, Colorado.

Advisors’ Opinion:

  • [By Motley Fool Transcribing]

    Bonanza Creek Energy (NYSE:BCEI) Q4 2018 Earnings Conference CallFeb. 28, 2019 12:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Shares of Bonanza Creek Energy Inc (NYSE:BCEI) have earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $41.67.

  • [By Joseph Griffin]

    Bonanza Creek Energy (NYSE:BCEI) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Bonanza Creek Energy (BCEI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Performing Stocks To Invest In 2021: Digirad Corporation(DRAD)

Digirad Corporation provides diagnostic solutions in the United States. The company operates in two segments, Diagnostic Services and Diagnostic Imaging. The Diagnostic Services segment provides in-office nuclear cardiology and ultrasound imaging, and cardiac event monitoring services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, or any combination of these procedures in their offices, hospitals, and imaging centers. The Diagnostic Imaging segment sells medical diagnostic imaging systems, including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides camera maintenance services to physician offices, hospitals, imaging centers, and mobile service providers. The company was founded in 1985 and is headquartered in Suwanee, Georgia.

Advisors’ Opinion:

  • [By ]

    Some of these are even smaller nano-caps, such as medical device maker Digirad (Nasdaq: DRAD), whose entire market value is just $36 million.

    There is absolutely nothing wrong with small businesses. I own shares of quite a few in my personal account. But for the most part, I use them to fill out the growth sleeve of my portfolio and don’t consider them stable income producers.

Top 10 Performing Stocks To Invest In 2021: Bluerock Residential Growth REIT, Inc.(BRG)

Bluerock Residential Growth REIT, Inc. (“we,” “us,” or the “Company”) was incorporated on July 25, 2008 under the laws of the state of Maryland.

We have elected to be treated, and currently qualify, as a real estate investment trust (or “REIT”) for federal income tax purposes. As a REIT, we generally are not subject to corporate-level income taxes. To maintain our REIT status, we are required, among other requirements, to distribute annually at least 90% of our “REIT taxable income,” as defined by the Internal Revenue Code of 1986, as amended (the “Code”), to our stockholders. If we fail to qualify as a REIT in any taxable year, we would be subject to federal income tax on our taxable income at regular corporate tax rates. We were incorporated to raise capital and acquire a diverse portfolio of residential real estate assets.   Advisors’ Opinion:

  • [By Shane Hupp]

    A number of research analysts have commented on BRG shares. Zacks Investment Research raised shares of Bluerock Residential Growth REIT from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Friday, February 15th. Boenning Scattergood reissued a “buy” rating and set a $11.00 target price on shares of Bluerock Residential Growth REIT in a research report on Tuesday, November 6th. B. Riley reissued a “buy” rating on shares of Bluerock Residential Growth REIT in a research report on Tuesday, November 6th. Finally, TheStreet raised shares of Bluerock Residential Growth REIT from a “d+” rating to a “c-” rating in a research report on Thursday, January 24th. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $11.17.

    COPYRIGHT VIOLATION NOTICE: “Bluerock Residential Growth REIT Inc (BRG) Shares Sold by National Asset Management Inc.” was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4188619/bluerock-residential-growth-reit-inc-brg-shares-sold-by-national-asset-management-inc.html.

    About Bluerock Residential Growth REIT

  • [By Shane Hupp]

    Bluerock Residential Growth REIT Inc Class A (NYSEAMERICAN:BRG) was the target of a large decrease in short interest in August. As of August 31st, there was short interest totalling 1,697,945 shares, a decrease of 7.7% from the August 15th total of 1,840,022 shares. Approximately 7.2% of the shares of the company are short sold. Based on an average daily trading volume, of 110,334 shares, the days-to-cover ratio is presently 15.4 days.

  • [By Ethan Ryder]

    Press coverage about Bluerock Residential Growth REIT (NASDAQ:BRG) has trended somewhat positive on Sunday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bluerock Residential Growth REIT earned a media sentiment score of 0.02 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.1792961215955 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Top 10 Performing Stocks To Invest In 2021: Transocean Inc.(RIG)

Transocean Ltd. provides offshore contract drilling services for oil and gas wells worldwide. It offers deepwater and harsh environment drilling, oil and gas drilling management, and drilling engineering and drilling project management services. The company also offers well and logistics services. In addition, it engages in oil and gas exploration, development, and production activities primarily in the United States offshore Louisiana and Texas, and in the United Kingdom sector of the North Sea. As of February 10, 2011, the company owned, had partial ownership interests in, and operated 138 mobile offshore drilling units, including 47 high-specification floaters, 25 midwater floaters, 9 high-specification jackups, 54 standard jackups, and 3 other rigs, as well as 1 ultra-deepwater floater and 3 high-specification jackups under construction. Transocean Ltd. was founded in 1953 and is based in Zug, Switzerland.

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of LASRY MARC’s stock buys and sells, go to https://www.gurufocus.com/guru/lasry+marc/current-portfolio/portfolio

    These are the top 5 holdings of LASRY MARCPacific Drilling SA (PACD) – 18,702,188 shares, 49.14% of the total portfolio. New PositionVistra Energy Corp (VST) – 6,438,245 shares, 29.01% of the total portfolio. Shares reduced by 5.78%Transocean Ltd (RIG) – 7,772,098 shares, 10.62% of the total portfolio. New PositionMidstates Petroleum Co Inc (MPO) – 3,494,914 shares, 5.17% of the total portfolio. Roan Resources Inc (ROAN) – 1,57

  • [By Tyler Crowe]

    This was one of those quarters where Transocean’s (NYSE:RIG) results aren’t necessarily reflective of the company’s accomplishments. Even though Transocean posted yet another quarterly loss, the company completed a major acquisition and netted some notable contract wins. These won’t show up on the financial statements for a while, but they are indicative of a company poised to do better in the future. 

Top 10 Performing Stocks To Invest In 2021: Celgene Corporation(CELG)

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Behçet’s disease, atopic dermatitis, and ulcerative colitis. The company’s products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; and Triphase Accelerator Corporation, as well as a strategic collaboration with Nurix, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Advisors’ Opinion:

  • [By Ethan Ryder]

    Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 114.66%. The business had revenue of $4.04 billion for the quarter, compared to analyst estimates of $3.98 billion. During the same quarter in the previous year, the business earned $2.00 earnings per share. Equities research analysts anticipate that Celgene Co. will post 10.01 EPS for the current fiscal year.

    ILLEGAL ACTIVITY WARNING: “Bank of The West Boosts Stake in Celgene Co. (CELG)” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4282863/bank-of-the-west-boosts-stake-in-celgene-co-celg.html.

    About Celgene

  • [By ]

    Bristol-Myers Squibb (NYSE: BMY), one of the largest U.S. pharma companies by revenue, didn’t waste any time scooping up biotech Celgene (Nasdaq: CELG). Announced on January 3, the $74 billion acquisition is the second-largest pharmaceutical M&A deal ever (after the $87 billion merger of Warner-Lambert and Pfizer (NYSE: PFE) twenty years ago).

Top 10 Performing Stocks To Invest In 2021: Fidelity Southern Corporation(LION)

Fidelity Southern Corporation operates as the holding company for Fidelity Bank, which provides financial products and services for business and retail customers primarily in the metropolitan Atlanta and northern Florida markets. The company accepts various deposit products, including savings deposits, noninterest-bearing demand deposits, interest-bearing demand deposits, money market accounts, time deposits, and brokered deposits. It also offers various loan products, including commercial and industrial loans, commercial loans secured by real estate, small business administration loans, construction and residential real estate loans, direct and indirect automobile loans, residential mortgage and home equity loans, secured and unsecured personal loans, and residential mortgage loans. In addition, the company offers Internet banking comprising online bill pay and mobile deposit, as well as Internet cash management services; and trust and wealth management services. Further, it provides cash management, remote deposit, and international trade business services; and merchant services for businesses and credit cards. Additionally, the company operates an insurance agency that offers consumer credit related insurance products; and issues trust preferred securities. As of March 31, 2015, it had a network of 45 branches. Fidelity Southern Corporation was founded in 1973 and is headquartered in Atlanta, Georgia.

Advisors’ Opinion:

  • [By Shane Hupp]

    Dimensional Fund Advisors LP boosted its stake in Fidelity Southern Co. (NASDAQ:LION) by 6.7% during the 1st quarter, HoldingsChannel reports. The firm owned 1,680,359 shares of the financial services provider’s stock after buying an additional 105,499 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.06% of Fidelity Southern worth $38,766,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    ValuEngine cut shares of Fidelity Southern (NASDAQ:LION) from a strong-buy rating to a buy rating in a research note published on Wednesday morning.

Best Blue Chip Stocks For 2019

The S&P 500 hit a bottom back in March 2009, spurring on a nine-year bull market. Odds are if you were in the market during this time you made some money, whether it was investing in the indices or equities. 24/7 Wall St. taking a look back to when the S&P 500 bottomed to see how some of the major blue chips have fared since then.

Back on March 6, 2009, the S&P 500 bottomed out at 666.79, and from there began perhaps the biggest bull market of the modern era. At the most recent close, the S&P 500 was at 2,677.67, more than quadrupling its bottom nearly nine years ago.

So how does Intel Corp. (NASDAQ: INTC) measure up?

On an adjusted close basis, Intel closed March 6, 2009, at $9.29 a share, or $12.41 on an unadjusted basis. Intel most recently closed at $47.84 on an adjusted basis.

On the surface, it’s obvious that Intel’s growth over this nine-year period outpaced the broad markets. To put some numbers to this, Intel shares gained roughly 415%. So if you had invested $1,000 in Intel back then, you would have $5,149.62 as of Thursday’s close.

Best Blue Chip Stocks For 2019: Research Frontiers Incorporated(REFR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Research Frontiers (REFR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    News articles about Research Frontiers (NASDAQ:REFR) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Research Frontiers earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave media stories about the technology company an impact score of 46.129953752672 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

  • [By Money Morning Staff Reports]

    However, Seven Star’s gains are already on the books. After looking at last week’s top performing penny stocks, we’ll show you a penny stock on the verge of jumping over 70%…

    Penny Stock Current Share Price Last Week’s Gain
    Seven Stars Cloud Group Inc. (Nasdaq: SSC) $4.49 175.13%
    Alliance MMA Inc. (Nasdaq: AMMA) $0.37 121.05%
    India Globalization Capital Inc. (NYSE: IGC) $1.14 74.38%
    Obalon Therapeutics Inc. (Nasdaq: OBLN) $3.23 63.16%
    Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.56 55.76%
    Atlanticus Holdings Corp. (Nasdaq: ATLC) $2.85 43.55%
    Research Frontiers Inc. (Nasdaq: REFR) $1.28 41.37%
    Koss Corp. (Nasdaq: KOSS) $4.08 41.28%
    GLG Life Tech Corp. (TSE: GLG) $0.88 33.90%
    Geron Corp. (Nasdaq: GERN) $4.76 32.40%

    While those gains are already in the book, you don’t have to miss out on the next penny stocks to soar.

  • [By Joseph Griffin]

    Research Frontiers, Inc. (NASDAQ:REFR) insider Kevin Douglas acquired 163,044 shares of the stock in a transaction on Tuesday, September 11th. The shares were purchased at an average cost of $0.92 per share, with a total value of $150,000.48. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Ethan Ryder]

    Research Frontiers (NASDAQ: REFR) and RPX (NASDAQ:RPXC) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Best Blue Chip Stocks For 2019: Odyssey Marine Exploration Inc.(OMEX)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    After looking at this week’s penny stock gainers, we’ll give you that leg up with one of our top-rated penny stocks from our proprietary stock ranking system…

    Penny Stock Current Share Price (March 26) Last Week’s Gain
    Cartesian Inc. (OTCMKTS: CRTN) $0.39 170.69%
    Odyssey Marine Exploration Inc. (Nasdaq: OMEX) $8.76 135.90%
    iFresh Inc. (Nasdaq: IFMK) $8.25 64.64%
    China Auto Logistics Inc. (Nasdaq: CALI) $4.68 47.43%
    National American University Holdings Inc. (Nasdaq: NAUH) $1.20 39.29%
    Document Security Systems Inc. (NYSE: DSS) $1.58 33.91%
    Blonder Tongue Labs Inc. (NYSE: BDR) $0.77 33.90%
    CareDx Inc. (Nasdaq: CDNA) $7.49 29.88%
    Mediwound Ltd. (Nasdaq: MDWD) $5.10 26.51%
    New York & Co. Inc. (NYSE: NWY) $3.37 26.35%

    Don’t Miss This Shot at a $78,000 Windfall: This tiny firm is about to make the entire world wire-free. As its game-changing technology revolutionizes the global power structure, its stock could hand investors a massive return. Learn more…

  • [By Joseph Griffin]

    News stories about Odyssey Marine Exploration (NASDAQ:OMEX) have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Odyssey Marine Exploration earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned media coverage about the business services provider an impact score of 46.3184749361846 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

  • [By Max Byerly]

    Odyssey Marine Exploration (NASDAQ: OMEX) and Teekay Offshore Partners (NYSE:TOO) are both small-cap transportation companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

  • [By Joseph Griffin]

    Kenon (NYSE: KEN) and Odyssey Marine Exploration (NASDAQ:OMEX) are both small-cap utilities companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Best Blue Chip Stocks For 2019: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Sean Williams]

    Arguably, one of the most dumbfounding effects of the ongoing stock market downturn has been the decline in drug developers like Celgene (NASDAQ:CELG)… as if the a declining stock market is going to halt or reduce sickness. Put simply, we can’t determine when we get sick or what ailment we’ll deal with, which means that drug developers tend to be mostly immune (save for drug-pricing power) to an economic contraction.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion.
    Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion.
    American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion.
    Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion.
    LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion.
    V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion.
    Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion.
    Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million.
    Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion.
    Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion.
    Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million.
    ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million.
    Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million.
    Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million.
    Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion.
    Genesis Energy, L.P
  • [By Todd Campbell]

    Celgene Corp. (NASDAQ:CELG) investors would probably like a few do-overs given the company’s stumbles over the past year. First, it suffered a key clinical-trial failure that forced it to ratchet back its long-term sales outlook. Then, the FDA sent it an embarrassing Refusal to File letter for its most-anticipated drug, ozanimod. 

  • [By Chris Lange]

    Celgene Corp.’s (NASDAQ: CELG) short interest for this settlement date dropped to 15.38 million shares from the previous level of 23.94 million. Shares were changing hands at $83.33, in a 52-week trading range of $74.13 to $147.17.

  • [By Brian Feroldi, Keith Speights, and Neha Chamaria]

    So which stocks do we think have been unfairly beaten down right now? We asked a team of Motley Fool investors to weigh in, and they called out Celgene (NASDAQ:CELG), Brookfield Infrastructure Partners (NYSE:BIP), and Universal Display (NASDAQ:OLED). 

Best Blue Chip Stocks To Invest In Right Now

Shutterstock

Fact: When interest rates rise, you need to be in dividend-growth stocks.

Proof: They’ve handily beaten the S&P 500 in the 17 months since the Federal Reserve put the zero-interest-rate era on ice.

In just a moment, I’ll show you 2 terrific off-the-radar dividend-growth plays to snap up now—and 2 surprising blue chips you’ll want to keep well away from your nest egg.

First, take a look at how the iShares Core Dividend-Growth ETF (DGRO) has performed vs. the SPDR S&P 500 ETF (SPY) on a total-return basis since December 16, 2015, the day Janet Yellen raised rates for the first time in nine years.

The Dividend-Growth Edge in 1 Chart

Best Blue Chip Stocks To Invest In Right Now: United States Steel Corporation(X)

Advisors’ Opinion:

  • [By Lee Jackson]

    This venerable steel producer remains a favorite on Wall Street.United States Steel Corp. (NYSE: X) produces and sells flat-rolled and tubular steel products in North America and Europe. It operates through three segments.Its Flat-Rolled Products segment offers slabs, rounds, strip mill plates, sheets and tin mill products. This segment serves customers in the automotive, consumer and the combined industrial, service center and mining commercial markets.

  • [By Peter Graham]

    One seemingly interesting bright spot though now that the sector has come off a bit is steel. Two steel stocks in United States Steel Corporation (X) and Steel Dynamics, Inc. (STLD) not only are looking technically attractive once again, they’re offering some nice value on a fundamental basis, albeit for very different reasons.

  • [By Logan Wallace]

    TMX Group Ltd (TSE:X) – Equities researchers at National Bank Financial lowered their Q3 2018 earnings per share estimates for shares of TMX Group in a research report issued on Monday, July 16th. National Bank Financial analyst J. Gloyn now forecasts that the company will post earnings of $1.30 per share for the quarter, down from their prior estimate of $1.33. National Bank Financial currently has a “Outperform” rating and a $88.00 price target on the stock. National Bank Financial also issued estimates for TMX Group’s Q4 2018 earnings at $1.35 EPS and FY2019 earnings at $5.68 EPS.

Best Blue Chip Stocks To Invest In Right Now: Franco-Nevada Corporation(FNV)

Advisors’ Opinion:

  • [By Reuben Gregg Brewer]

    This, however, is where streaming company Wheaton Precious Metals (NYSE:WPM)and its peers Royal Gold (NASDAQ:RGLD) and Franco-Nevada (NYSE:FNV)come into play. Streaming companies provide cash up front to miners for the right to buy gold and silver in the future at reduced rates. Often miners use the money to build new mines. Wheaton provided $625 million in cash to Barrick for the development of Pascua-Lama. That is just one of 10 development projects in which Wheaton has invested. Its portfolio also contains 17 operating mines.

  • [By Ethan Ryder]

    Franco Nevada Corp (NYSE:FNV) (TSE:FNV) has received an average recommendation of “Hold” from the twelve research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $95.17.

  • [By Dan Caplinger]

    Franco-Nevada (NYSE:FNV) has done a good job recently of expanding its reach. After focusing almost exclusively on streaming agreements with mining partners in gold and other precious and base metals, the company decided recently to boost its exposure to oil and gas considerably. That’s proven to be an important move, as weaker gold production has been offset by better performance in its growing energy portfolio.

Best Blue Chip Stocks To Invest In Right Now: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Todd Campbell]

    It’s been a tough year for Celgene Corp. (NASDAQ:CELG)investors, but upcoming phase 3 dataon luspaterceptfromAcceleron Pharma (NASDAQ:XLRN)could rekindle interest in Celgene’s stock price. Acceleron is expected to report trial results for luspatercept in myelodysplastic syndromes (MDS) and beta thalassemia anytime now, and if the results are positive, Celgene thinks luspatercept could be a multibillion-dollar-per-year blockbuster.

  • [By Todd Campbell]

    In collaboration with Celgene Corp. (NASDAQ:CELG), Acceleron Pharma is developing luspatercept, an erythroid maturation agent (EMA) that addresses chronic anemia in MDS and beta-thalassemia by promoting the production of healthy red blood cells.

  • [By George Budwell]

    Shares of blue-chip biotech Celgene Corporation (NASDAQ:CELG) fell by a staggering 23.9% through the first six months of this year,according to data fromS&P Global Market Intelligence. The biotech’s former high-flying ways were halted this year by a slew of headwinds that all center around the upcoming patent expiration for the top-selling multiple myeloma drug Revlimid.

  • [By George Budwell]

    Top healthcare stocks CVS Health Corporation (NYSE:CVS) and Celgene Corporation (NASDAQ:CELG), for example, come across as downright bargains for a variety of reasons right now. Read on the find out more.

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) has been the hands-down winner over Celgene (NASDAQ:CELG) in terms of stock performance over the last year. It’s the same story for revenue generated. Celgene beat Amgen in earnings, but only because of a technicality: Amgen incurred a big one-time tax hit in 2017.

  • [By Paul Ausick]

    Lingering outside the spotlight of the top 10 most shorted Nasdaq stocks again in the most recent period were Celgene Corp. (NASDAQ: CELG), Cisco Systems Inc. (NASDAQ: CSCO) and Twenty-First Century Fox Inc. (NASDAQ: FOXA).

Best Blue Chip Stocks To Invest In Right Now: bluebird bio, Inc.(BLUE)

Advisors’ Opinion:

  • [By Keith Speights]

    Bellicum Pharmaceuticals (NASDAQ:BLCM) and bluebird bio (NASDAQ:BLUE) are both clinical-stage biotechs that are developing cutting-edge therapies to treat cancer and other diseases. But the fortunes of these two biotechs have been very different over the last 12 months. Bellicum stock is down 37% during the period, while Bluebird’s share price has soared more than 125%.

  • [By Ethan Ryder]

    Blue Protocol (CURRENCY:BLUE) traded 5.2% lower against the US dollar during the one day period ending at 18:00 PM ET on June 27th. In the last seven days, Blue Protocol has traded down 29.4% against the US dollar. Blue Protocol has a total market capitalization of $3.16 million and approximately $3,034.00 worth of Blue Protocol was traded on exchanges in the last 24 hours. One Blue Protocol token can currently be bought for approximately $0.0862 or 0.00001406 BTC on exchanges including IDEX, YoBit, CoinExchange and EtherDelta (ForkDelta).

  • [By Todd Campbell]

    Celgene is working with bluebird bio (NASDAQ:BLUE) on bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy for use in multiple myeloma. Initially, bb2121 is being studied in the fourth-line or higher setting, where there’s a significant need for new treatment. However, data observed so far suggests that it may eventually wind up being a successor to Revlimid and Pomalyst.

  • [By Stephan Byrd]

    bluebird bio (NASDAQ:BLUE)‘s stock had its “underweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report issued on Wednesday.

Best Blue Chip Stocks To Invest In Right Now: Apple Inc.(AAPL)

Advisors’ Opinion:

  • [By Ashraf Eassa]

    It’s widely rumored that Apple(NASDAQ:AAPL) intends to launch three new iPhone models this year. At the bottom of the product stack is supposed to be a device with a liquid crystal display (LCD) that measures 6.1 inches along the diagonal.

  • [By Evan Niu, CFA]

    This all comes as Apple(NASDAQ:AAPL) is preparing to take Apple News to the next level in iOS 12, incorporating the service across other apps and services while redesigning the interface and bringing it to the Mac. Apple is taking news curation and distribution very seriously, presumably ahead of its rumored launch of a premium news subscription.

  • [By Paul Ausick]

    Qualcomm reaffirmed its “high confidence” that the merger will result in adjusted EPS in fiscal year 2019 of $6.75 to $7.50, excluding royalties and other revenues from Apple Inc. (NASDAQ: AAPL) and other licensees currently disputing payments to Qualcomm. The adjusted EPS figure includes a $1 billion cost reduction program and a boost of $1.50 in EPS from NXP.

  • [By Evan Niu, CFA]

    In addition to growing its services business, we know that Apple (NASDAQ:AAPL) is working on a new suite of audio accessories, including premium over-ear headphones that would compete with market leaders like Bose. The Mac maker has also been widely reported to be working on second-generation AirPods, which have proven to be a sleeper hit; the next version will likely include water resistance as a headline selling feature.

  • [By Douglas A. McIntyre]

    Apple Inc. (NASDAQ: AAPL) is the most valuable company in America based on market cap and is unlikely to let go of that position in the foreseeable future. However, the race for second place has tightened as Microsoft Corp. (NASDAQ: MSFT) has caught up with Amazon.com Inc. (NASDAQ: AMZN).

Best Blue Chip Stocks To Invest In Right Now: Schwab US Large-Cap ETF (SCHX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Milestone Group Inc. decreased its stake in Schwab US Large-Cap ETF (NYSEARCA:SCHX) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 63,425 shares of the company’s stock after selling 2,710 shares during the period. Schwab US Large-Cap ETF makes up 0.7% of Milestone Group Inc.’s investment portfolio, making the stock its 19th largest holding. Milestone Group Inc.’s holdings in Schwab US Large-Cap ETF were worth $4,001,000 as of its most recent filing with the Securities & Exchange Commission.

Hot Warren Buffett Stocks To Own For 2019

If you’re looking for good Warren Buffett stocks to buy, there’s no better option than Buffett’s former money guy. I’m talking, of course, about Lou Simpson, the long-time Geico portfolio manager, who retired at the end of 2010 after 31 years at the company, more than a third of them spent under Berkshire Hathaway Inc. (NYSE:BRK.A, NYSE:BRK.B) ownership.

It’s hard to believe that the legendary investment manager, who outperformed the S&P 500 in 18 out of 25 years between 1980 and 2004, has been retired for more than seven years. Boy does time fly.

Simpson grew bored of retirement very quickly, so the veteran money set up SQ Advisors, an investment advisory firm with $200 million in assets under management that would handle money for friends, family and some charities.

Charging 1% annually with no performance fees, Simpson was just happy to have something to do every day that he enjoyed and could help people. Fast forward to the end of 2017 and Simpson’s managing $3.1 billion in assets invested in just 14 stocks.

Hot Warren Buffett Stocks To Own For 2019: Zynga Inc.(ZNGA)

Advisors’ Opinion:

  • [By Chris Lange]

    Zynga Inc. (NASDAQ: ZNGA) shares made a small gain on Wednesday after Wedbush said that it can see this stock making about a 50% run over the next year and that a turnaround is underway.

  • [By Shane Hupp]

    Zynga (NASDAQ: ZNGA) and iPass (NASDAQ:IPAS) are both consumer discretionary companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Zynga (ZNGA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Zynga (ZNGA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lee Jackson]

    This is a very aggressive tech play that could have upside above the current price targets. Zynga Inc. (NASDAQ: ZNGA) is a leading developer of mobile and social games. In the company’s relatively short history, it has developed a broad portfolio of games that includes several games on Facebook and several top-grossing mobile apps. Key franchises include FarmVille, Zynga Poker, Hit It Rich Slots and Words With Friends.

  • [By Shane Hupp]

    Zynga (NASDAQ: ZNGA) is one of 61 publicly-traded companies in the “Data processing & preparation” industry, but how does it weigh in compared to its rivals? We will compare Zynga to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, institutional ownership, risk and profitability.

Hot Warren Buffett Stocks To Own For 2019: Discovery Communications, Inc.(DISCA)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on DISCOVERY COMMUNICATIONS INC. Common Stock (DISCA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin] Companies Reporting Before The Bell
    Dean Foods Company (NYSE: DF) is projected to report quarterly earnings at $0.11 per share on revenue of $1.85 billion.
    Discovery, Inc. (NASDAQ: DISCA) is expected to report quarterly earnings at $0.44 per share on revenue of $1.99 billion.
    Jacobs Engineering Group Inc. (NYSE: JEC) is estimated to report quarterly earnings at $0.89 per share on revenue of $3.63 billion.
    Henry Schein, Inc. (NASDAQ: HSIC) is expected to report quarterly earnings at $0.92 per share on revenue of $3.17 billion.
    Gartner, Inc. (NYSE: IT) is projected to report quarterly earnings at $0.57 per share on revenue of $926.18 million.
    The AES Corporation (NYSE: AES) is estimated to report quarterly earnings at $0.24 per share on revenue of $2.98 billion.
    Expeditors International of Washington, Inc. (NASDAQ: EXPD) is projected to report quarterly earnings at $0.64 per share on revenue of $1.71 billion.
    US Foods Holding Corp. (NYSE: USFD) is expected to report quarterly earnings at $0.32 per share on revenue of $5.98 billion.
    DISH Network Corporation (NASDAQ: DISH) is expected to report quarterly earnings at $0.7 per share on revenue of $3.50 billion.
    Zebra Technologies Corporation (NASDAQ: ZBRA) is estimated to report quarterly earnings at $2.06 per share on revenue of $936.98 million.
    Camping World Holdings, Inc. (NYSE: CWH) is expected to report quarterly earnings at $0.42 per share on revenue of $1.06 billion.
    Perrigo Company plc (NYSE: PRGO) is projected to report quarterly earnings at $1.14 per share on revenue of $1.21 billion.
    Petróleo Brasileiro S.A. – Petrobras (NYSE: PBR) is estimated to report quarterly earnings at $0.28 per share on revenue of $23.80 billion.
    JD.com, Inc. (NYSE: JD) is projected to report quarterly earnings at $0.18 per share on revenue of $15.65 billion.
    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is projected to report quarterly earnings at $0.6 per share o
  • [By Stephan Byrd]

    BidaskClub upgraded shares of DISCOVERY COMMUNICATIONS INC. Common Stock (NASDAQ:DISCA) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

  • [By Billy Duberstein]

    You might thinkDiscovery Inc.’s (NASDAQ:DISCA) (NASDAQ:DISCK) (NASDAQ:DISCB) stations primarily feature nature videos and celebrity cooks, but did you know it’s actually becoming a player on the international sports scene? While known for its namesake Discovery Channel and documentary brands such as The Learning Channel, HGTV, and the Food Network, Discovery has actually been in the sports business since 2012, when it first acquired a minority stake in European sports channel Eurosport. Discovery was apparently pleased enough with the channel’s progress to buy 100% of Eurosport in July 2015, and that year, Eurosport won the exclusive rights to broadcast the Olympics in Europe from 2018-2022.

Hot Warren Buffett Stocks To Own For 2019: XTL Biopharmaceuticals Ltd.(XTLB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Verastem, Inc. (NASDAQ: VSTM) fell 9.7 percent to $4.73 in pre-market trading after announcing a $35 million common stock offering.
    Evolus, Inc. (NASDAQ: EOLS) shares fell 8 percent to $13.48 in pre-market trading ahead of regulatory update at 8:30 a.m. ET.
    XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) fell 6.5 percent to $2.01 in pre-market trading after climbing 10.50 percent on Tuesday.
    Purple Innovation, Inc. (NASDAQ: PRPL) shares fell 5.8 percent to $9.36 in pre-market trading after reporting Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) fell 5.7 percent to $5.15 in pre-market trading after declining 5.04 percent on Tuesday.
    RYB Education, Inc. (NYSE: RYB) shares fell 5 percent to $16.39 in pre-market trading following Q1 results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares fell 4.4 percent to $4.30 in pre-market trading after rising 40.62 percent on Tuesday.
    Arbor Realty Trust, Inc. (NYSE: ABR) fell 4.4 percent to $8.92 in pre-market trading after announcing a 5.5 million share common stock offering.
    Daxor Corporation (NYSE: DXR) fell 4.1 percent to $7.32 in pre-market trading.
    Ormat Technologies, Inc. (NYSE: ORA) shares fell 3.8 percent to $51.03 in pre-market trading after the company announced plans to restate its Q2, Q3, Q4 and FY 2017 financial statements.
    Canadian Solar Inc. (NASDAQ: CSIQ) fell 3.5 percent to $16.20 in pre-market trading after reporting Q1 results.
    CELYAD SA/ADR (NASDAQ: CYAD) shares fell 3.3 percent to $29.70 in pre-market trading after the company reported launch of 1.8 million share offering

Hot Warren Buffett Stocks To Own For 2019: Energizer Holdings, Inc.(ENR)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    SenesTech, Inc. (NASDAQ: SNES) shares surged 296.07 percent to close at $1.25 on Monday after the California Department of Pesticide Regulation proposed to register the company's ContraPest for sale and use in California.
    AgEagle Aerial Systems, Inc. (NASDAQ: UAVS) shares gained 19.59 percent to close at $2.93.
    TransGlobe Energy Corporation (NASDAQ: TGA) rose 18.39 percent to close at $2.64 on Monday.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) shares gained 15.91 percent to close at $2.55.
    VAALCO Energy, Inc. (NYSE: EGY) shares jumped 14.9 percent to close at $2.39.
    Resonant Inc. (NASDAQ: RESN) climbed 13.96 percent to close at $4.49.
    Chesapeake Energy Corporation (NYSE: CHK) shares rose 13.55 percent to close at $4.61 on Monday.
    Lilis Energy, Inc. (NYSE: LLEX) surged 13.09 percent to close at $5.01.
    MB Financial, Inc. (NASDAQ: MBFI) gained 12.9 percent to close at $49.28. Fifth Third Bancorp (NASDAQ: FITB) agreed to acquire MB Financial for $54.70 per share in cash and stock.
    TransEnterix, Inc. (NYSE: TRXC) shares rose 12.83 percent to close at $3.43.
    World Wrestling Entertainment, Inc. (NYSE: WWE) jumped 12.52 percent to close at $57.86 on Reports that it has reached a deal with Fox for Its 'Smackdown Live' program.
    Eastman Kodak Company (NASDAQ: KODK) rose 12.38 percent to close at $5.90.
    NuCana plc (NASDAQ: NCNA) climbed 11.94 percent to close at $26.44. NuCana appointed Dr. Cyrille Leperlier to its Board as an independent non-executive Director.
    Aqua Metals, Inc. (NASDAQ: AQMS) rose 11.83 percent to close at $3.97 on Monday.
    Huami Corporation (NYSE: HMI) shares jumped 11.27 percent to close at $10.17 following Q1 results.
    21Vianet Group, Inc. (NASDAQ: VNET) gained 9.55 percent to close at $7.34.
    Boxlight Corporation (NASDAQ: BOXL) rose 8.56 percent to close at $7.86 after the company announced an exclusive partnership with Multi Touch Interactives to strengthen the de
  • [By Lisa Levin] Gainers
    SenesTech, Inc. (NASDAQ: SNES) shares jumped 113.5 percent to $0.6737 after the California Department of Pesticide Regulation proposed to register the company's ContraPest for sale and use in California.
    AgEagle Aerial Systems, Inc. (NASDAQ: UAVS) shares rose 35.34 percent to close at $3.32.
    Art's-Way Manufacturing Co., Inc. (NASDAQ: ARTW) shares gained 30.36 percent to $3.65.
    Xtant Medical Holdings, Inc. (NYSE: XTNT) shares jumped 25.6 percent to $7.4701 after the company disclosed that it has received the FDA clearance for InTice™-C Porous Titanium Cervical Interbody System.
    VAALCO Energy, Inc. (NYSE: EGY) shares surged 20 percent to $2.495.
    TransGlobe Energy Corporation (NASDAQ: TGA) surged 17.04 percent to $2.61.
    Boxlight Corporation (NASDAQ: BOXL) gained 15 percent to $8.32 after the company announced an exclusive partnership with Multi Touch Interactives to strengthen the development of next generation interactive educational activities.
    Arcimoto, Inc. (NASDAQ: FUV) gained 15 percent to $3.39.
    MB Financial, Inc. (NASDAQ: MBFI) rose 13.7 percent to $49.64. Fifth Third Bancorp (NASDAQ: FITB) agreed to acquire MB Financial for $54.70 per share in cash and stock.
    FRONTEO, Inc. (NASDAQ: FTEO) shares rose 11.8 percent to $20.956.
    TransEnterix, Inc. (NYSE: TRXC) shares jumped 11.1 percent to $3.38.
    21Vianet Group, Inc. (NASDAQ: VNET) rose 10.6 percent to $7.41.
    NII Holdings, Inc. (NASDAQ: NIHD) shares gained 9 percent to $2.32.
    Kelly Services, Inc. (NASDAQ: KELYA) rose 7.6 percent to $24.19. Northcoast Research upgraded Kelly Services from Neutral to Buy.
    LaSalle Hotel Properties (NYSE: LHO) shares climbed 5.6 percent to $33.70. Blackstone Group LP (NYSE: BX) will buy LaSalle Hotel Properties in a $4.8 billion deal, Bloomberg reported.
    Alteryx, Inc. (NYSE: AYX) gained 5.5 percent to $32.56. KeyBanc upgraded Alteryx from Sector Weight to Overweight.
    Energizer Holdings, Inc. (NYSE:

Hot Warren Buffett Stocks To Own For 2019: Skechers U.S.A., Inc.(SKX)

Advisors’ Opinion:

  • [By Todd Campbell and Timothy Green]

    Buying and holding shares in great companies like eBayfor the long haul has proven to be very profit-friendly, but identifying growth stocks early on isn’t easy. To help find tomorrow’s winners, we asked two Motley Fool investors which burgeoning growth stocks are on their radar right now. They responded with Skechers (NYSE:SKX)and Mimecast (NASDAQ:MIME). Read on to find out if these stocks deserve a spot in your portfolio.

  • [By Matthew Cochrane]

    Now that we’ve defined value investing, highlighted a few metrics that value investors look for, and warned investors to watch out for value traps, let’s take a closer look at stocks that I believe are trading at prices below their intrinsic value today. While representing very different industries, the one thing that AFLAC Incorporated (NYSE:AFL), Skechers USA Inc (NYSE:SKX), and Verizon Communications Inc (NYSE:VZ) all have in common is that, based on each company’s fundamentals, they appear to be some of the best bargainsavailable in the stock market today.

  • [By ]

    A Growth Stock Masquerading As A Value Stock
    Skechers (NYSE: SKX): is the fast growing footwear company located in Manhattan Beach, California. The company is riding a huge secular trend of international growth fueled principally by growth in India and China.

  • [By ]

    Skechers USA (SKX) : “I think they’re doing well. I think it’s really good and they’ve done a good job.”

    Kratos Defense & Security (KTOS) : “This one is a battleground and I don’t want to be there.”

  • [By Chris Lange]

    When Skechers USA Inc. (NYSE: SKX) reported its most recent quarterly results after the markets closed on Thursday, the company said that it had $0.75 in earnings per share (EPS) on $1.25 billion in revenue. The consensus estimates had called for $0.75 in EPS on revenue of $1.2 billion. The first quarter of last year reportedly had EPS of $0.60and $1.07 billion in revenue.

Hot Warren Buffett Stocks To Own For 2019: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Paul Ausick]

    Celgene Corp. (NASDAQ: CELG) dropped about 5.6% Monday to post a new 52-week low of $74.13. Shares closed at $78.37 on Friday and the stock’s 52-week high is $147.17. Volume of around 16.3 million shares was more than double the daily average.The company was one of several named last week in an FDA report of drugmakers who may be illegally blocking delaying access to cheaper generic copies of brand-name drugs. Then today, word got out that the firm’s chief business development officer had retired in April.

  • [By ]

    First up, Celgene Corp. (NADSAQ:CELG) plunked down $9 billion to acquire Juno Therapeutics (NASDAQ:JUNO) and get ahold of its promising line of CAR-T cancer treatments. The announcement juiced JUNO shares by more than 25% on the day, bringing its five day gains to an eye-popping 75%.

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB),Celgene Corporation (NASDAQ:CELG), andGilead Sciences Inc.(NASDAQ:GILD) around this time in 1998 would have made you a millionaire already.

  • [By Logan Wallace]

    Investors sold shares of Celgene (NASDAQ:CELG) on strength during trading hours on Friday. $125.14 million flowed into the stock on the tick-up and $200.18 million flowed out of the stock on the tick-down, for a money net flow of $75.04 million out of the stock. Of all stocks tracked, Celgene had the 12th highest net out-flow for the day. Celgene traded up $2.16 for the day and closed at $84.54

  • [By Keith Speights]

    Celgene (NASDAQ:CELG) claims the best-selling orphan drug of 2017 with Revlimid. The blood cancer drug raked in over $5.5 billion in U.S. sales last year and generated another $2.8 billion outside of the U.S.While U.S. sales grew nearly 23% year over year, most of the increase stemmed from price increases. Celgene has been criticized by the U.S. Food and Drug Administration (FDA) for the steep price hikes for Revlimid.

  • [By Keith Speights]

    What’s the riskiest big biotech stock on the market? According to market research firm EvaluatePharma, it’sCelgene (NASDAQ:CELG).

    Many investors have been very bearish about Celgene for months. The company’s once-promising Crohn’s disease drug GED-0301 flopped miserably in a late-stage clinical study in October 2017. Celgene thoroughly embarrassed itself, with the FDA refusing to review the regulatory submission of ozanimod in treating multiple sclerosis (MS). Largely because of these major setbacks, Celgene stock has plunged 45% over the last eight and a half months.

Top 10 Undervalued Stocks For 2018

I believe Valero Energy (NYSE:VLO) shares are currently an undervalued long-term buy at current levels, based on its high free cash flow yield of over 10% and significant discount to its fair/intrinsic value. Additionally, I believe the company will continue to enjoy high returns on capital invested because of its sustainable competitive advantages. In this article I will explain the company’s economic moat and how I came up with the fair value.

Valero is the world’s largest independent refiner. Valero owns 15 refineries, with a combined throughput of over 3.1 million barrels per day. Valero is also one of North America’s largest ethanol producers with 11 plants. They produce a combined capacity of 1.4 billion gallons per year (85,000 BPD) ethanol production capacity. Valero is also significantly expanding its midstream assets through its master limited partnership Valero Energy Partners LP (NYSE:VLP).

Source: Valero Investor Relations

Top 10 Undervalued Stocks For 2018: Oxford Industries Inc.(OXM)

Advisors’ Opinion:

  • [By Joseph Griffin]

    GW&K Investment Management LLC raised its stake in Oxford Industries (NYSE:OXM) by 1.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 357,935 shares of the textile maker’s stock after acquiring an additional 4,019 shares during the period. GW&K Investment Management LLC owned approximately 2.13% of Oxford Industries worth $26,688,000 as of its most recent SEC filing.

Top 10 Undervalued Stocks For 2018: YRC Worldwide Inc.(YRCW)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Monday, the industrial shares surged 1.55 percent. Meanwhile, top gainers in the sector included Kelly Services, Inc. (NASDAQ: KELYA), up 9 percent, and YRC Worldwide Inc. (NASDAQ: YRCW) up 6 percent.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on YRC Worldwide (YRCW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Marten Transport (NASDAQ: MRTN) and YRC Worldwide (NASDAQ:YRCW) are both small-cap transportation companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations and valuation.

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 155.56 percent to close at $5.75 on Thursday.
    Inspire Medical Systems, Inc. (NYSE: INSP) shares gained 56.12 percent to close at $24.98. Inspire Medical went public Thursday on the New York Stock Exchange. The company issued 6.75 million shares priced at $16 each.
    Presbia PLC (NASDAQ: LENS) shares rose 53.02 percent to close at $3.55.
    Integrated Media Technology Limited (NASDAQ: IMTE) shares rose 46.29 percent to close at $32.11. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months.
    Technical Communications Corporation (NASDAQ: TCCO) climbed 27.78 percent to close at $5.75.
    STAAR Surgical Company (NASDAQ: STAA) shares gained 26.27 percent to close at $21.15 after reporting upbeat Q1 results.
    Sharing Economy International Inc. (NASDAQ: SEII) shares jumped 22.16 percent to close at $4.30 on Thursday after gaining 9.32 percent on Wednesday.
    China Advanced Construction Materials Group, Inc. (NASDAQ: CADC) rose 20.45 percent to close at $2.65 on Thursday.
    YRC Worldwide Inc. (NASDAQ: YRCW) surged 18.36 percent to close at $9.99 following upbeat quarterly earnings.
    MYR Group Inc. (NASDAQ: MYRG) jumped 17.68 percent to close at $35.74 after the company posted strong Q1 earnings.
    Xspand Products Lab Inc (NASDAQ: XSPL) jumped 17.4 percent to close at $5.87. Xspand Products priced its IPO at $5 per share.
    Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose 17.32 percent to close at $14.90. Coherus BioSciences reported resubmission of BLA for CHS-1701.
    Rudolph Technologies, Inc. (NASDAQ: RTEC) shares gained 17.17 percent to close at $31.05 following upbeat quarterly earnings.
    The Meet Group, Inc. (NASDAQ: MEET) gained 16.02 percent to close at $2.68 following Q1 earnings.
    Ca

Top 10 Undervalued Stocks For 2018: Global Eagle Entertainment Inc.(ENT)

Advisors’ Opinion:

  • [By Ethan Ryder]

    ENTCash (ENT) is a PoW/PoS coin that uses the X11 hashing algorithm. ENTCash’s total supply is 600,000,000 coins. ENTCash’s official website is entcash.com. ENTCash’s official Twitter account is @Eternity_Group and its Facebook page is accessible here.

  • [By Joseph Griffin]

    Eternity (CURRENCY:ENT) traded 14.6% lower against the U.S. dollar during the 1 day period ending at 7:00 AM ET on May 28th. Over the last seven days, Eternity has traded 31.6% lower against the U.S. dollar. Eternity has a market capitalization of $156,350.00 and $1,349.00 worth of Eternity was traded on exchanges in the last day. One Eternity coin can currently be bought for approximately $0.0366 or 0.00000506 BTC on exchanges including YoBit, Trade Satoshi and Livecoin.

  • [By Garrett Baldwin]

    Retail stocks are in focus after the U.S. Census Bureau released monthly sales figures before the bell Tuesday. The bureau said that retail sales increased by 0.3% in April, a figure that matched trade expectations. Markets had expected consumer spending to increase, however home improvement sales were not the major factor that most expected. This was evident from The Home Depot’s earnings report. Markets are increasingly optimistic over U.S. trade negotiations with China. Chinese President Xi Jinping’s No. 1 economic advisor will visit the United States this week to continue the nation’s dialogue with America. In addition, roughly 100 companies and trade associations will be sounding off to the Trump administration about the potential impact of tariffs in the Chinese markets.
    Stocks to Watch Today: TSLA, AMZN, GS
    Amazon.com Inc. (Nasdaq: AMZN) is in focus thanks to tax policy in Seattle. On Monday, the Seattle’s City Council passed a bill that will tax Amazon and 131 other companies $275 per employee each year in order to create a fund to address homelessness in the Seattle. The tax is half what was originally proposed and remains a contentious issue for Amazon, which is the city’s biggest employer. Goldman Sachs Group (NYSE: GS) is sounding the alarm about the state of the markets. The company warned that the U.S. budget deficit is increasing while America’s unemployment rate is falling. This hasn’t occurred since the World War II. The bank believes that the combination of the two could cause the Fed to spike interest rates in the near future. This comes at a time when the Fed has already lost control of interest rates. Look for additional earnings reports from Eagle Materials Inc. (NYSE: EXP), Bitauto Holding Ltd.(Nasdaq: BITA), Virtusa Corp. (Nasdaq: VRTU), Global Eagle Entertainment Inc.(Nasdaq: ENT), and Kamada Ltd. (Nasdaq: KMDA).

    FollowMoney MorningonFacebook,Twitter, andLinkedIn.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Global Eagle Entertainment (ENT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Undervalued Stocks For 2018: Highwoods Properties, Inc.(HIW)

Advisors’ Opinion:

  • [By Shane Hupp]

    Daiwa Securities Group Inc. trimmed its holdings in Highwoods Properties, Inc. (NYSE:HIW) by 98.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,100 shares of the real estate investment trust’s stock after selling 1,987,006 shares during the period. Daiwa Securities Group Inc.’s holdings in Highwoods Properties were worth $925,000 as of its most recent SEC filing.

Top 10 Undervalued Stocks For 2018: icad inc.(ICAD)

Advisors’ Opinion:

  • [By Lisa Levin]

     

    Losers
    Netshoes (Cayman) Limited (NASDAQ: NETS) shares dipped 43.73 percent to close at $2.87 on Tuesday as the company posted downbeat Q1 results.
    Cesca Therapeutics Inc. (NASDAQ: KOOL) shares dropped 29.01 percent to close at $0.80 after reporting Q1 results.
    SenesTech, Inc. (NASDAQ: SNES) shares fell 22.2 percent to close at $0.340 after reporting Q1 miss.
    Vipshop Holdings Limited (NYSE: VIPS) fell 19.95 percent to close at $12.08 after the company reported weaker-than-expected earnings for its first quarter on Monday.
    Image Sensing Systems, Inc. (NASDAQ: ISNS) fell 19.68 percent to close at $3.775 after reporting earnings were down year over year. First quarter earnings came in flat, down from 4 cents per share in the same quarter of last year. Sales came in at $3.01 million.
    Boxlight Corporation (NASDAQ: BOXL) dropped 18.47 percent to close at $9.62 on Tuesday after surging 77.44 percent on Monday.
    ENDRA Life Sciences Inc. (NASDAQ: NDRA) declined 16.21 percent to close at $2.43. ENDRA Life Sciences is expected to release quarterly earnings today.
    ALJ Regional Holdings, Inc. (NASDAQ: ALJJ) shares fell 16.13 percent to close at $1.79.
    Switch Inc (NYSE: SWCH) shares dropped 14.93 percent to close at $13.16 following a first-quarter earnings miss.
    Restoration Robotics Inc (NASDAQ: HAIR) fell 14.42 percent to close at $3.68 after reporting a first-quarter earnings miss.
    iCAD, Inc. (NASDAQ: ICAD) declined 13.01 percent to close at $3.41 following Q1 results.
    Intersections Inc. (NASDAQ: INTX) fell 12.44 percent to close at $1.97.
    Histogenics Corporation (NASDAQ: HSGX) declined 12.24 percent to close at $2.15.
    AZZ Inc. (NYSE: AZZ) fell 12.1 percent to close at $39.60 following Q3 earnings.
    Hallador Energy Company (NASDAQ: HNRG) fell 11.1 percent to close at $6.49.
    Integrated Media Technology Limited (NASDAQ: IMTE) dropped 10.66 percent to close at $16.93 on Tuesday.
    Myomo, Inc. (NYSE: MYO) slipp

Top 10 Undervalued Stocks For 2018: TC PipeLines, LP(TCP)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Most investors have probably heard of energy giants Royal Dutch Shell (NYSE:RDS-A) (NYSE:RDS-B), Dominion Energy (NYSE:D), and TransCanada (NYSE:TRP). Fewer, however, are likely familiar with their publicly traded master limited partnerships (MLPs): Shell Midstream Partners (NYSE:SHLX), Dominion Energy Midstream Partners (NYSE:DM), and TC Pipelines (NYSE:TCP). That might be a good thing, as the market has beaten up the latter trio this year, sending their valuations south.

  • [By Lisa Levin] Gainers
    Shineco, Inc. (NASDAQ: TYHT) rose 34.7 percent to $2.29 in pre-market trading following Q3 results. Shineco posted Q3 earnings of $0.21 per share on sales of $13.3 million.
    Carver Bancorp, Inc. (NASDAQ: CARV) rose 15.8 percent to $12.74 in pre-market trading after surging 201.37 percent on Thursday.
    LiveXLive Media, Inc. (NASDAQ: LIVX) shares rose 11.5 percent to $7.75 in pre-market trading after climbing 64.50 percent on Thursday.
    Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) rose 9 percent to $18.30 in pre-market trading after climbing 41.77 percent on Thursday.
    AmTrust Financial Services Inc (NASDAQ: AFSI) rose 6.2 percent to $14.25 in pre-market trading after a 13D filing from Carl Icahn shows a new 9.38 percent stake in the company. The filing also shows language from Icahn that strongly opposes a go-private transaction.
    Cerner Corporation (NASDAQ: CERN) rose 5.6 percent to $64.02 in pre-market trading after the Department of Veterans Affairs reported an agreement with Cerner Government Services, Inc. to provide seamless care for veterans.
    PetroChina Company Limited (NYSE: PTR) shares rose 5.3 percent to $82.05 in pre-market trading.
    TC PipeLines, LP (NYSE: TCP) shares rose 5.2 percent to $26.59 in the pre-market trading session.
    IQVIA Holdings Inc. (NYSE: IQV) shares rose 4.8 percent to $102.50 in pre-market trading as the company pulled secondary offering 'in light of recent market conditions'.
    Axon Enterprise, Inc. (NASDAQ: AAXN) rose 4.5 percent to $59.70 in pre-market trading. On Thursday, Axon priced its 4.3 million share offering of common stock at $53 per share.
    The Trade Desk, Inc. (NASDAQ: TTD) rose 4.5 percent to $84 in pre-market trading.
    PetIQ Inc (NASDAQ: PETQ) rose 3.9 percent to $18.96 in pre-market trading after a 13G filing shows a new 5.05 percent stake by the State of New Jersey's Division of Investment.
    Mattel, Inc. (NASDAQ: MAT) shares rose 3.7 percent to $15.85 in pre-market
  • [By Matthew DiLallo]

    That funding progress is important given an unexpected development in the quarter when the Federal Regulatory Commission (FERC) revised a long-standing policy and will no longer allow master limited partnerships to collect an allowance for income taxes on certain pipelines. That change could have a major impact on the cash flows of TransCanada’s MLP TC Pipelines, LP (NYSE:TCP). While TC Pipelines isn’t sure how much this change will impact its cash flow, it took precautionary actions by slashing its distribution to investors. That payout reduction and the related uncertainty has weighed significantly on TC Pipelines’ valuation. Because of that, Girling said that “further dropdowns of assets by TransCanada into TC Pipelines is not considered a viable funding option at this time,” and he isn’t sure if it will be one in the future. However, he did clarify that even without future dropdowns to TC Pipelines, TransCanada believes it has the “financial capacity to fund our existing capital program through our predictable and growing cash flow from operations as well as several other funding alternatives.”

  • [By Lisa Levin] Gainers
    Integrated Media Technology Limited (NASDAQ: IMTE) rose 30.8 percent to $22.00 in pre-market trading after declining 18.63 percent on Monday.
    Nevsun Resources Ltd. (NYSE: NSU) rose 14.5 percent to $3.40 in pre-market trading after Lundin Mining Corporation and Euro Sun Mining Inc. proposed to acquire Nevsun Resources for around C$1.5 billion.
    Sharing Economy International Inc. (NASDAQ: SEII) rose 15.2 percent to $4.25 in pre-market trading after the company disclosed that it entered into a license agreement with Ecrent Capital Holdings Limited.
    Veeco Instruments Inc. (NASDAQ: VECO) shares rose 14.1 percent to $19.50 in pre-market trading after reporting stronger-than-expected earnings for its first quarter.
    Impinj, Inc. (NASDAQ: PI) rose 13.4 percent to $15.40 in pre-market trading after reporting Q1 results.
    SandRidge Energy, Inc. (NYSE: SD) shares rose 13.2 percent to $16.45 in pre-market trading following Q1 results.
    Blink Charging Co. (NASDAQ: BLNK) rose 12.6 percent to $4.55 in pre-market trading after jumping 171.14 percent on Monday.
    Crocs, Inc. (NASDAQ: CROX) shares rose 10 percent to $16.66 in pre-market trading after the company reported better-than-expected earnings for its first quarter and issued strong sales forecast for the second quarter.
    Pareteum Corporation (NASDAQ: TEUM) rose 9.7 percent to $3.05 in pre-market trading after announcing Q1 results.
    Dean Foods Company (NYSE: DF) rose 8 percent to $9.00 in pre-market trading after reporting upbeat Q1 earnings.
    Fiesta Restaurant Group, Inc. (NASDAQ: FRGI) rose 7.3 percent to $23.45 in pre-market trading following Q1 results.
    IAMGOLD Corporation (NYSE: IAG) rose 7.1 percent to $6.09 in pre-market trading after reporting upbeat Q1 earnings.
    TC PipeLines, LP (NYSE: TCP) rose 6.4 percent to $27 in pre-market trading after gaining 2.08 percent on Monday.
    Carrols Restaurant Group, Inc. (NASDAQ: TAST) rose 6.3 percent to $11.75 in pre-market trading fol

Top 10 Undervalued Stocks For 2018: Siebert Financial Corp.(SIEB)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    William may be right about a sell-off in stocks… in the cryptocurrency space. Over the last week, companies that have billed themselves as blockchain-focused saw their stocks surge. One firm – Long Island Iced Tea changed its name to Long Island Blockchain and watched its stock surge more than triple digits. But today, firms with this exposure are cratering. MGT Capital Investments Inc. (OTCMKTS: MGTI), Long Island Iced Tea Corp. (Nasdaq: LTEA), Riot Blockchain Inc. (Nasdaq: RIOT), and Siebert Financial Corp. (Nasdaq: SIEB) all fell by more than 12% Friday.

Top 10 Undervalued Stocks For 2018: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By ]

    Merck & Co. (MRK) , Johnson & Johnson (JNJ) and Celgene Inc. (CELG) may be wondering what has gotten into U.S. Senator Cory Booker, who represents their home state of New Jersey.

  • [By Chris Lange]

    Celgene Corp.s (NASDAQ: CELG) short interest for this settlement date remained flat at 15.65 million shares. Shares were changing hands at $89.14, in a 52-week trading range of $84.25 to $147.17.

  • [By Brian Orelli]

    Data source: Bluebird.

    What happened with Bluebird this quarter?
    Without any drugs on the market, revenue and earnings aren’t particularly important for Bluebird. For the record, the company lost $115 million in the first quarter on a GAAP basis. The cash situation is arguably more important. While the change in its nest egg looks like Bluebird is being extremely frugal, the biotech actually receivedan additional $48.6 million in the first quarter from its secondary offering, negating some of the cash burn. The original Northstar (HGB-204) phase 1/2 trial completed two years of follow-up, allowing Bluebird to submit its marketing application for LentiGlobin in Europe later this year. Given the solid data for bb2121, its anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T cell (CAR T) therapy, Bluebird elected to co-develop the treatment with its partner Celgene (NASDAQ:CELG).

    Image source: Getty Images.

  • [By Keith Noonan, Keith Speights, and Nicholas Rossolillo]

    How promising is EDIT-101? Enough to attract the attention of Allergan (NYSE:AGN). The big drugmaker paid $90 million up front to Editas in 2017 for the option to license up to five of the small biotech’s programs, including EDIT-101. Juno Therapeutics, which was acquired earlier this year by Celgene (NASDAQ:CELG), has also partnered with Editas to use CRISPR in genetically engineering T cells for cancer therapies.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion.
    Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion.
    American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion.
    Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion.
    LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion.
    V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion.
    Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion.
    Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million.
    Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion.
    Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion.
    Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million.
    ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million.
    Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million.
    Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million.
    Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion.
    Genesis Energy, L.P
  • [By Logan Wallace]

    Celgene (NASDAQ:CELG) announced that its Board of Directors has approved a stock repurchase program, which allows the company to buyback $3.00 billion in shares on Thursday, May 24th. This buyback authorization allows the biopharmaceutical company to buy up to 5.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Top 10 Undervalued Stocks For 2018: Dominion Resources, Inc.(D)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Dominion Energy (NYSE:D) started 2018 well, delivering results that came in at the high end of its forecast thanks to much colder weather than last winter. Because of that, the utility believes its full-year results will come in above the midpoint of its guidance range. The company also affirmed its dividend growth forecast even though two factors helping to power it — the SCANA (NYSE:SCG) merger and its ability to grow its master limited partnershipDominion Energy Midstream Partners (NYSE:DM) — have become increasingly uncertain.

  • [By Paul Ausick]

    Dominion Energy Inc. (NYSE: D) traded down about 1.5% Thursday and posted a new 52-week low of $63.91 after closing Wednesday at $64.88. The stock’s 52-week high is $85.30. Volume totaled around 3 million, about a 40% below the daily average. The company had no specific news.

  • [By Max Byerly]

    Dominion Energy (NYSE:D) insider Thomas F. Farrell II bought 4,000 shares of the stock in a transaction dated Thursday, May 10th. The stock was purchased at an average cost of $63.44 per share, with a total value of $253,760.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Top 10 Undervalued Stocks For 2018: Transocean Inc.(RIG)

Advisors’ Opinion:

  • [By Max Byerly]

    ValuEngine upgraded shares of Transocean (NYSE:RIG) from a hold rating to a buy rating in a research note released on Wednesday morning.

    Several other research firms have also recently issued reports on RIG. Bank of America increased their price objective on Transocean from $12.00 to $13.00 and gave the stock a neutral rating in a research report on Wednesday, April 18th. Citigroup increased their price objective on Transocean from $15.00 to $16.00 and gave the stock a buy rating in a research report on Monday, April 30th. Susquehanna Bancshares set a $11.00 price objective on Transocean and gave the stock a hold rating in a research report on Friday, January 12th. Cowen set a $11.00 price objective on Transocean and gave the stock a hold rating in a research report on Thursday, January 11th. Finally, Piper Jaffray set a $11.00 price objective on Transocean and gave the stock a hold rating in a research report on Wednesday, January 10th. Eight investment analysts have rated the stock with a sell rating, ten have given a hold rating and fourteen have issued a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $11.79.

  • [By The Ticker Tape]

    TD Ameritrade clients appeared to take some profits in multiple names during the period. Oil companies were popular sells with ConocoPhillips (NYSE: COP), BP  PLC (ADR) (NYSE: BP), National-Oilwell Varco Inc. (NYSE: NOV), and Transocean LTD (NYSE: RIG) all net sold. Oil prices traded near three-year highs on higher global demand and possible OPEC-led production cuts. COP and BP both traded at multi-year highs, while NOV and RIG reached 52-week highs, enticing clients to take profits in all four names. Alcoa Corp. (NYSE: AA) traded at levels not seen since before the financial crisis following proposed tariffs on steel and aluminum, and was net sold. For the third month in a row, Facebook, Inc. (NASDAQ: FB) was net sold after CEO Mark Zuckerberg testified before Congress regarding the misuse of user data and a beat on earnings.

  • [By Jason Hall]

    So what’s an investor to do? Owning the companies best-positioned to profit is a great place to start. Consider two of Big Oil’s finest inRoyal Dutch Shell plc (ADR)(NYSE:RDS-A)(NYSE:RDS-B)andTotal SA (ADR)(NYSE:TOT), offshore drillerTransocean LTD(NYSE:RIG) and natural gas for transportation specialistClean Energy Fuels Corp(NASDAQ:CLNE).

  • [By Logan Wallace]

    American International Group Inc. grew its position in shares of Transocean LTD (NYSE:RIG) by 7.7% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 872,019 shares of the offshore drilling services provider’s stock after buying an additional 62,611 shares during the quarter. American International Group Inc.’s holdings in Transocean were worth $8,633,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

  • [By Ethan Ryder]

    Quantitative Systematic Strategies LLC bought a new stake in Transocean LTD (NYSE:RIG) during the 1st quarter, HoldingsChannel reports. The institutional investor bought 13,609 shares of the offshore drilling services provider’s stock, valued at approximately $135,000.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
    Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
    Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
    Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
    Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
    vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
    Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
    Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
    Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
    GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
    Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market

Top 10 Undervalued Stocks To Invest In Right Now

Although you wouldnt necessarily know it from the relative performance of other banks in its weight class, Farmers Capital (NASDAQ:FFKT) has taken some meaningful self-improvement steps over the last couple of years. These moves have put the company on a path toward better interest spreads, better efficiency ratios, and better growth prospects, all of which should support higher earnings and returns in the coming years.

The valuation argument isnt quite as clean as Id like it to be. The shares do look undervalued on the basis of near-term returns on equity and EPS/EPS growth, not to mention what the shares could fetch in a potential acquisition, but Id like to see a little more discount relative to my long-term earnings growth expectations. At worst, though, this looks like a decent buy that could reward investors if 2018 results come in a little stronger than expected.

A Small Player With A Valuable Niche

Farmers Capital is a small bank no matter how you look at it around $300 million in market cap, under $1.7 billion in assets, and just 34 branches in operation. But what Farmers Capital may lack in size, I believe it can compensate in value, as the bank has a respectable business in Kentuckys Golden Triangle (an area including Cincinnati, Lexington, and Louisville, with above-average population and income growth relative to the region).

Top 10 Undervalued Stocks To Invest In Right Now: Maui Land & Pineapple Company, Inc.(MLP)

Advisors’ Opinion:

  • [By ]

    A flurry of mergers in the master-limited partnership (MLP) segment for pipeline companies rocked the energy sector on Thursday, drawing a sanguine response from Wall Street analysts that generally supported the new, more simplified structures.

Top 10 Undervalued Stocks To Invest In Right Now: Equity Commonwealth(EQC)

Advisors’ Opinion:

  • [By Stephan Byrd]

    HRPT Properties Trust (NYSE:EQC) had its price target boosted by investment analysts at JMP Securities to $33.00 in a report issued on Tuesday. The brokerage currently has a “market outperform” rating on the real estate investment trust’s stock. JMP Securities’ target price points to a potential upside of 4.04% from the company’s previous close.

  • [By Matthew DiLallo]

    Equity Commonwealth (NYSE:EQC) continued to steadily sell off its portfolio of real estate holdings, closing three more sales during the quarter, bringing its property count down to 13. As a result, cash flow kept declining. That trend doesn’t show any signs of ending given that the company has more properties on the market and doesn’t yet see a good opportunity to make acquisitions.

Top 10 Undervalued Stocks To Invest In Right Now: Chimerix, Inc.(CMRX)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Chimerix Inc (NASDAQ:CMRX) Director Ernest Mario sold 45,000 shares of the firm’s stock in a transaction dated Friday, May 18th. The shares were sold at an average price of $4.80, for a total value of $216,000.00. Following the transaction, the director now owns 12,905 shares of the company’s stock, valued at $61,944. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Top 10 Undervalued Stocks To Invest In Right Now: Communications Systems Inc.(JCS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Cara Therapeutics, Inc. (NASDAQ: CARA) shares surged 42.76 percent to close at $16.56 on Wednesday in reaction to a new licensing agreement with Europe-based Vifor Pharma. As part of the agreement, the biopharmaceutical company that alleviates pain licensed worldwide rights (except U.S., Japan, and South Korea) to Vifor Pharma to commercialize its KORSUVA therapy to Vifor $70 million.
    Yangtze River Port and Logistics Limited (NASDAQ: YRIV) gained 31.28 percent to close at $7.05 on Wednesday.
    Tiffany & Co. (NYSE: TIF) climbed 23.29 percent to close at $126.05 after the company reported upbeat results for its first quarter and raised its FY2018 earnings guidance.
    EVO Payments, Inc. (NASDAQ: EVOP) gained 18.88 percent to close at $19.02. EVO Payments priced its IPO at $16 per share.
    Carver Bancorp, Inc. (NASDAQ: CARV) rose 16.1 percent to close at $6.85.
    USA Technologies, Inc. (NASDAQ: USAT) gained 15.68 percent to close at $13.65 after announcing pricing of public offering.
    eXp World Holdings, Inc. (NASDAQ: EXPI) shares jumped 15.01 percent to close at $17.70.
    Geron Corporation (NASDAQ: GERN) gained 14.99 percent to close at $4.68.
    Evolus, Inc. (NASDAQ: EOLS) rose 14.62 percent to close at $19.36.
    Ralph Lauren Corporation (NYSE: RL) shares rose 14.34 percent to close at $133.33 after the company reported stronger-than-expected results for its fourth quarter.
    Turtle Beach Corporation (NASDAQ: HEAR) jumped 13.26 percent to close at $17.34 on Wednesday. Turtle Beach S-3 showed registration for 1.857 million share common stock offering via selling holders.
    Communications Systems, Inc. (NASDAQ: JCS) rose 13.18 percent to close at $3.95. Communications Systems reported establishment of special committee to explore strategic alternatives.
    Immutep Limited (NASDAQ: IMMP) shares climbed 12.95 percent to close at $2.53.
    xG Technology, Inc. (NASDAQ: XGTI) rose 12.64 percent to close at $0.8561 after the company&rsq

Top 10 Undervalued Stocks To Invest In Right Now: Synchronoss Technologies Inc.(SNCR)

Advisors’ Opinion:

  • [By Dan Caplinger]

    The stock market had a generally solid performance on Monday, with large-cap indexes posting modest gains even as benchmarks that track the changes of smaller stocks underperformed. The big news of the day came on the trade front, where the White House intervened to reverse previous policy with respect to Chinese smartphone giant ZTE in an apparent effort to gain favor with the world’s most populous nation and second-largest economic power. Investors looked for potential winners from the thawing of relations with China, but not all stocks were able to avoid significant losses. Viacom (NASDAQ:VIAB), Synchronoss Technologies (NASDAQ:SNCR), and DHX Media (NASDAQ:DHXM) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Timothy Green]

    Shares of Synchronoss Technologies (NASDAQ:SNCR) were suspended from trading on the Nasdaq on Monday due to the company’s failure to satisfy the Nasdaq listing requirements. Synchronoss hasn’t filed a quarterly or annual report with the SEC since February 2017 due to an ongoing financial restatement process. The stock will be quoted on the OTC markets under the same trading symbol during the suspension period. The stock dropped about 7% in pre-market trading.

  • [By Lisa Levin] Gainers
    Precipio, Inc. (NASDAQ: PRPO) jumped 43.3 percent to $0.5447 after the micro-cap specialty diagnostics company reported preliminary first-quarter results. The company said its first quarter revenue rose 286 percent from the same quarter a year ago to $712,000.
    Galectin Therapeutics, Inc. (NASDAQ: GALT) gained 34.5 percent to $4.52 after the company announced it would proceed with Phase 3 development of GR-MD-02 for NASH Cirrhosis following the FDA meeting.
    Boxlight Corporation (NASDAQ: BOXL) shares rose 21.9 percent to $8.1063.
    Evolus, Inc. (NASDAQ: EOLS) shares surged 16 percent to $15.65.
    Myomo, Inc. (NYSE: MYO) shares jumped 15.5 percent to $3.6263 after the company disclosed that its application for Medicare codes received favorable preliminary decision.
    Tandem Diabetes Care, Inc. (NASDAQ: TNDM) rose 13.7 percent to $10.12.
    ProPhase Labs, Inc. (NASDAQ: PRPH) gained 13.7 percent to $4.6743.
    Acacia Communications, Inc. (NASDAQ: ACIA) shares gained 12.2 percent to $35.34 as optical sector is seeing strength following President Trump's announcement that he would work with China related to ZTE Corp.
    Tailored Brands, Inc. (NYSE: TLRD) shares rose 11.3 percent to $35.17. Jefferies upgraded Tailored Brands from Hold to Buy.
    Kona Grill, Inc. (NASDAQ: KONA) jumped 10.6 percent to $2.875.
    Federated National Holding Company (NASDAQ: FNHC) shares rose 10.6 percent to $20.29. Raymond James upgraded Federated National Holding from Outperform to Strong Buy.
    Renewable Energy Group, Inc. (NASDAQ: REGI) climbed 10.2 percent to $15.15. Renewable Energy will replace Synchronoss Technologies Inc. (NASDAQ: SNCR) in the S&P SmallCap 600 on Tuesday, May 15.
    Stein Mart, Inc. (NASDAQ: SMRT) shares climbed 10.1 percent to $3.16. Stein Mart is expected to release Q1 earnings on May 23.
    NXP Semiconductors N.V. (NASDAQ: NXPI) rose 9.7 percent to $108.60 after Bloomberg reported that the China’s Commerce Ministry has restar

Top 10 Undervalued Stocks To Invest In Right Now: Genesee & Wyoming, Inc.(GWR)

Advisors’ Opinion:

  • [By Max Byerly]

    Piermont Capital Management Inc. decreased its position in Genesee & Wyoming (NYSE:GWR) by 8.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,850 shares of the transportation company’s stock after selling 890 shares during the quarter. Piermont Capital Management Inc.’s holdings in Genesee & Wyoming were worth $697,000 as of its most recent SEC filing.

Top 10 Undervalued Stocks To Invest In Right Now: STORE Capital Corporation(STOR)

Advisors’ Opinion:

  • [By Keith Speights]

    Verizon Communications (NYSE:VZ), Store Capital Corporation (NYSE:STOR), and Sanofi (NYSE:SNY) are three Warren Buffett stocks that have especially high dividend yields of more than 4%. What does the Oracle of Omaha like about these stocks — and are they smart picks for other investors right now?

  • [By Brian Feroldi, Leo Sun, and Demitrios Kalogeropoulos]

    Want proof? We asked these Motley Fool investors to highlight a dividend stock that pays a higher yield than Verizon. Here’s why they pickedTanger Factory Outlets (NYSE:SKT), Cedar Fair (NYSE:FUN), andSTORE Capital (NYSE:STOR).

  • [By Lee Jackson]

    STORE Capital Corp. Inc. (NYSE: STOR) is the leader in the acquisition, investment and management of Single Tenant Operational Real Estate, which is its target market. Investors receive a 4.94% yield, and shares traded recently at $24.85. The 52-week range is $19.65 to $26.58. The consensus price target is $27.08.

Top 10 Undervalued Stocks To Invest In Right Now: Travelzoo Inc.(TZOO)

Advisors’ Opinion:

  • [By Max Byerly]

    Travelzoo (NASDAQ: TZOO) and CACI (NYSE:CACI) are both retail/wholesale companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

  • [By Lisa Levin] Gainers
    Daré Bioscience, Inc. (NASDAQ: DARE) shares jumped 56.69 percent to close at $1.27 on Wednesday on news that the company entered into worldwide license agreement for Juniper Pharmaceuticals' intravaginal ring technology platform.
    Vicor Corporation (NASDAQ: VICR) rose 26.84 percent to close at $37.10. Vicor posted Q1 earnings of $0.10 per share on sales of $65.2 million.
    AGM Group Holdings Inc. (NASDAQ: AGMH) climbed 25.56 percent to close at $10.61.
    Travelzoo (NASDAQ: TZOO) gained 24.7 percent to close at $9.75 following strong Q1 results.
    Intrepid Potash, Inc. (NYSE: IPI) shares climbed 19.24 percent to close at $4.71.
    China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 18.73 percent to close at $18.64.
    Genprex, Inc. (NASDAQ: GNPX) climbed 18.28 percent to close at $5.89. Genprex expanded its operations to Cambridge, Mass.
    Scorpio Tankers Inc. (NYSE: STNG) rose 13.92 percent to close at $2.70 following Q1 results.
    Rocky Brands, Inc. (NASDAQ: RCKY) shares surged 13.57 percent to close at $23.85 after reporting Q1 results.
    Resonant Inc. (NASDAQ: RESN) shares rose 12.5 percent to close at $4.14 on Wednesday.
    USANA Health Sciences, Inc. (NYSE: USNA) jumped 11.24 percent to close at $106.85 following Q1 results.
    SUPERVALU Inc. (NYSE: SVU) rose 11.16 percent to close at $16.24 after the company reported Q4 results and agreed to sell and leaseback eight distribution centers for an aggregate purchase price of $483 million.
    K12 Inc. (NYSE: LRN) shares gained 10.74 percent to close at $15.36 following Q3 results.
    Tupperware Brands Corporation (NYSE: TUP) rose 9.15 percent to close at $46.28 as the company posted in-line quarterly earnings.
    Six Flags Entertainment Corporation (NYSE: SIX) shares climbed 8.49 percent to close at $64.18 as the company posted a narrower-than-expected loss for its first quarter.
    Carlisle Companies Incorporated (NYSE: CSL) gained 8.2 percent to close at $107.94 af
  • [By Lisa Levin]

    Shares of Travelzoo (NASDAQ: TZOO) got a boost, shooting up 30 percent to $10.16 following strong Q1 results.

    Six Flags Entertainment Corporation (NYSE: SIX) shares were also up, gaining 8 percent to $64.01 as the company posted a narrower-than-expected loss for its first quarter.

  • [By Lisa Levin]

    Shares of Travelzoo (NASDAQ: TZOO) got a boost, shooting up 25 percent to $9.70 following strong Q1 results.

    Six Flags Entertainment Corporation (NYSE: SIX) shares were also up, gaining 9 percent to $64.54 as the company posted a narrower-than-expected loss for its first quarter.

Top 10 Undervalued Stocks To Invest In Right Now: Universal Health Services, Inc.(UHS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Quorum Health (NYSE: QHC) and Universal Health Services (NYSE:UHS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.

  • [By Max Byerly]

    Parametrica Management Ltd acquired a new stake in Universal Health Services (NYSE:UHS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,694 shares of the health services provider’s stock, valued at approximately $201,000.

Top 10 Undervalued Stocks To Invest In Right Now: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Keith Speights]

    Celgene (NASDAQ:CELG) has certainly had its challenges over the last year, but you wouldn’t have known it from the company’s first-quarter results. The big biotech announced on Friday that its Q1 revenue jumped 20% year over year, with adjusted diluted earnings per share soaring 23%.

  • [By Motley Fool Staff]

    Stock No. 1: The first one up, alphabetically, is Celgene (NASDAQ:CELG). The ticker symbol is CELG. Celgene, two years ago, was at $101 a share. Celgene, as of Monday’s market close was down to $84.57. So, not such a great stock pick of mine. Celgene down 16%. The market up 30%. So, we’re going to have to log a minus 46% to start this review of my stocks from five years ago, as Celgene has dropped a little and the market, as we’ve already established, has done quite well.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion.
    Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion.
    American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion.
    Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion.
    LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion.
    V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion.
    Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion.
    Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million.
    Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion.
    Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion.
    Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million.
    ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million.
    Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million.
    Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million.
    Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion.
    Genesis Energy, L.P

day trading penny stocks

In this segment from the Motley Fool Money podcast, host Chris Hill is joined by Jason Moser of Million Dollar Portfolio, David Kretzmann of Hidden Gems Canada, and Aaron Bush of Motley Fool Rule Breakers to discuss the recent accounting woes at WageWorks (NYSE:WAGE). The provider of employee benefit plans has launched an investigation after reporting it inflated some of its profit and revenue figures. As a result, the CEO, CFO, and general counsel have all left the company — a major loss of leadership at a critical time.

A full transcript follows the video.

This video was recorded on April 6, 2018.

Chris Hill: WageWorks making headlines this week, and not the good kind. The CEO and Chief Financial Officer of the employee benefits company are gone, following an internal investigation that found WageWorks inflated some of their profit and revenue numbers. Jason, this used to be one of your stocks.

Jason Moser: You know, Chris, I like to dabble with watercolors. And one thing I’ve found in watercolor is, very often, less is more. You can really do a lot more with the painting with less. In the case of executive leadership, really, less is not more. And when we look at what’s going on here, CEO Joe Jackson, out. CFO, just retired. Senior Vice President, General Counsel, gone. I mean, this company has lost a lot of leadership in a short period of time. A little bit of an exodus there. This leads one to believe that maybe leadership made some big mistakes here, and I think the restatements speak to that as well.

day trading penny stocks: Marsh & McLennan Companies, Inc.(MMC)

Advisors’ Opinion:

  • [By Max Byerly]

    Marsh & McLennan Companies (NYSE: MMC) and Kering (OTCMKTS:PPRUY) are both large-cap finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

day trading penny stocks: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By ]

    Cramer was bearish on Xilinx (XLNX) , Celgene (CELG) , Exelixis (EXEL) , Moneygram (MGI) , Monster Beverage (MNST) , SunCoke Energy Partners (SXCP) and Mattel (MAT) .

  • [By Brian Orelli]

    Celgene(NASDAQ:CELG) started the year off with a solid first quarter, leading management to raise its 2018 guidance already.

    Celgene results: The raw numbers

    Metric

  • [By Dan Caplinger]

    BeiGene was almost an unknown name a year ago, but the Chinese biopharma company got a big boost when news hit last July that it would collaborate with biotech giant Celgene (NASDAQ:CELG). Under the terms of the deal, Celgene got rights to non-Asian global sales of a BeiGene candidate treatment for fighting solid cancer tumors. In exchange, BeiGene got the rights to sell Celgene’s Abraxane, Revlimid, and Vidaza in the Chinese market, as well as $263 million in cash, a $150 million equity investment, and Celgene’s existing commercial operations within China.

day trading penny stocks: Raytheon Company(RTN)

Advisors’ Opinion:

  • [By ]

    In the Lightning Round, Cramer was bullish on Bank of Internet (BOFI) , MGM Resorts (MGM) , Verizon (VZ) , Chipotle Mexican Grill (CMG) , Oracle (ORCL) , Salesforce.com (CRM) , PayPal (PYPL) , Raytheon (RTN) and McDonald’s (MCD) .

  • [By ]

    Cramer and the AAP team say that the president’s moves on behalf of Boeing (BA) signal good times for defense names, including Raytheon (RTN) . Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By ]

    Cramer and the AAP team say that the president’s moves on behalf of Boeing (BA) signal good times for defense names, including Raytheon (RTN) . Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By Lisa Levin] Companies Reporting Before The Bell
    General Motors Company (NYSE: GM) is projected to report quarterly earnings at $1.24 per share on revenue of $34.66 billion.
    Bristol-Myers Squibb Company (NYSE: BMY) is estimated to report quarterly earnings at $0.85 per share on revenue of $5.24 billion.
    United Parcel Service, Inc. (NYSE: UPS) is expected to report quarterly earnings at $1.55 per share on revenue of $16.44 billion.
    Time Warner Inc. (NYSE: TWX) is projected to report quarterly earnings at $1.74 per share on revenue of $7.91 billion.
    ConocoPhillips (NYSE: COP) is expected to report quarterly earnings at $0.74 per share on revenue of $8.81 billion.
    PepsiCo, Inc. (NYSE: PEP) is expected to report quarterly earnings at $0.93 per share on revenue of $12.4 billion.
    American Airlines Group Inc. (NASDAQ: AAL) is estimated to report quarterly earnings at $0.72 per share on revenue of $10.42 billion.
    Southwest Airlines Co (NYSE: LUV) is expected to report quarterly earnings at $0.74 per share on revenue of $5.01 billion.
    Fiat Chrysler Automobiles N.V. (NYSE: FCAU) is estimated to report quarterly earnings at $0.8 per share on revenue of $34.52 billion.
    Union Pacific Corporation (NYSE: UNP) is projected to report quarterly earnings at $1.66 per share on revenue of $5.38 billion.
    D.R. Horton, Inc. (NYSE: DHI) is expected to report quarterly earnings at $0.85 per share on revenue of $3.76 billion.
    The Hershey Company (NYSE: HSY) is estimated to report quarterly earnings at $1.4 per share on revenue of $1.94 billion.
    Praxair, Inc. (NYSE: PX) is expected to report quarterly earnings at $1.56 per share on revenue of $2.94 billion.
    Altria Group, Inc. (NYSE: MO) is projected to report quarterly earnings at $0.92 per share on revenue of $4.63 billion.
    Shire plc (NASDAQ: SHPG) is estimated to report quarterly earnings at $3.54 per share on revenue of $3.72 billion.
    Oshkosh Corporation (NYSE: OSK) is projected to report quarter
  • [By ]

    Raytheon (RTN) : “I think Raytheon is one of the best defense names.”

    Tallgrass Energy Partners (TEP) : “That dividend is a red flag. That group has become a house of pain and I’m not going there.”

day trading penny stocks: Enerplus Corporation(ERF)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Enerplus (NYSE:ERF) (TSE:ERF) – Stock analysts at National Bank Financial reduced their FY2018 earnings estimates for Enerplus in a research note issued on Thursday, May 3rd. National Bank Financial analyst T. Wood now forecasts that the oil and natural gas company will earn $1.13 per share for the year, down from their previous estimate of $1.27. National Bank Financial also issued estimates for Enerplus’ FY2019 earnings at $1.96 EPS.

  • [By Max Byerly]

    Enerplus (TSE:ERF) (NYSE:ERF) had its target price hoisted by CIBC from C$19.00 to C$20.00 in a research note published on Friday morning.

    Other research analysts also recently issued research reports about the stock. CSFB upped their price objective on shares of Enerplus from C$17.00 to C$20.00 in a report on Friday, April 13th. GMP Securities upped their price objective on shares of Enerplus from C$17.00 to C$18.00 in a report on Thursday, March 1st. Barclays upped their price objective on shares of Enerplus from C$18.00 to C$20.00 in a report on Monday, February 26th. Canaccord Genuity upped their price objective on shares of Enerplus from C$16.50 to C$17.00 in a report on Monday, February 26th. Finally, Desjardins upped their price objective on shares of Enerplus from C$16.00 to C$17.50 in a report on Monday, February 26th. Seven equities research analysts have rated the stock with a buy rating, The stock has an average rating of Buy and an average price target of C$18.29.

day trading penny stocks: 21Vianet Group, Inc.(VNET)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million.
    Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results.
    Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27.
    Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating.
    PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat.
    NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399.
    Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643.
    Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16.
    Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results.
    GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results.
    The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st
  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares climbed 31.68 percent to close at $7.19 on Wednesday. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares gained 24.15 percent to close at $3.29. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    21Vianet Group, Inc. (NASDAQ: VNET) shares surged 24 percent to close at $6.82.
    Check-Cap Ltd. (NASDAQ: CHEK) gained 20.25 percent to close at $4.87.
    HUYA Inc. (NYSE: HUYA) shares surged 18.42 percent to close at $22.50
    Abaxis, Inc. (NASDAQ: ABAX) rose 16.15 percent to close at $83.34. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    Pain Therapeutics, Inc. (NASDAQ: PTIE) shares jumped 16.07 percent to close at $10.62.
    Bilibili Inc. (NASDAQ: BILI) rose 16.04 percent to close at $14.11.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) gained 14.88 percent to close at $6.33.
    Phoenix New Media Limited (NYSE: FENG) rose 13.96 percent to close at $5.55.
    Daqo New Energy Corp. (NYSE: DQ) jumped 13.88 percent to close at $67.27 on Wednesday.
    Sea Limited (NYSE: SE) jumped 12.59 percent to close at $11.98 after reporting Q1 results.
    Viking Therapeutics, Inc. (NASDAQ: VKTX) rose 12.01 percent to close at $5.13.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) gained 11.93 percent to close at $3.19.
    Boot Barn Holdings, Inc. (NYSE: BOOT) climbed 11.66 percent to close at $24.52 on Wednesday after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Macy's, Inc. (NYSE: M) rose 10.83 percent to close at $33.17 after the company reported stronger-than-expected results for its first quarter and lifted guidance.
    ChemoCentryx, Inc. (NASDAQ: CCXI) gained 9.36 percent to close at $12.50. Canaccord Genuity initiated coverage on ChemoCentryx with a Buy rating.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX)

Top 5 Medical Stocks To Watch For 2018

Hospitals may soon have to post their standard prices for patients online, under a proposed rule unveiled Tuesday by the Trump administration.

Also, the administration is seeking comments on how to stop so-called surprise billing — when patients are charged after unknowingly being seen by out-of-network providers — and how to give patients better information about the out-of-pocket costs they will face.

And officials are ramping up pressure on hospitals to give patients better access to their medical records electronically or face a penalty.

The proposed rule is the Centers for Medicare & Medicaid Services’ latest effort to give patients more information about the cost of health care and about their own medical history so they can better direct their own care. The guidance — part of the annual update to Medicare payment policies — applies mainly to Medicare patients and providers, but officials expect it will influence practices across the nation’s health care system. It would take effect in 2019.

Top 5 Medical Stocks To Watch For 2018: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) has been the hands-down winner over Celgene (NASDAQ:CELG) in terms of stock performance over the last year. It’s the same story for revenue generated. Celgene beat Amgen in earnings, but only because of a technicality: Amgen incurred a big one-time tax hit in 2017.

  • [By ]

    First up, Celgene Corp. (NADSAQ:CELG) plunked down $9 billion to acquire Juno Therapeutics (NASDAQ:JUNO) and get ahold of its promising line of CAR-T cancer treatments. The announcement juiced JUNO shares by more than 25% on the day, bringing its five day gains to an eye-popping 75%.

  • [By ]

    Take for example the recent deal struck by Celgene Corp (NASDAQ: CELG) to purchase Juno Therapeutics (NASDAQ: JUNO) for $9 million.

    The news pushed Juno shares to a 52-week highs to end January, as reported by Yahoo Finance.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion.
    Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion.
    American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion.
    Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion.
    LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion.
    V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion.
    Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion.
    Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million.
    Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion.
    Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion.
    Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million.
    ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million.
    Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million.
    Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million.
    Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion.
    Genesis Energy, L.P

Top 5 Medical Stocks To Watch For 2018: SORL Auto Parts Inc.(SORL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Red Violet, Inc. (NASDAQ: RDVT) rose 75.31 percent to close at $9.94 after reporting Q1 results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 40.62 percent to close at $4.50 on Tuesday after reporting 2017 year-end results.
    MEI Pharma, Inc. (NASDAQ: MEIP) gained 34.39 percent to close at $3.40.
    MEDIGUS Ltd/S ADR (NASDAQ: MDGS) gained 32.74 percent to close at $1.50 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia.
    Pfenex Inc. (NYSE: PFNX) surged 31.15 percent to close at $8.00 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) rose 21.07 percent to close at $11.09. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors.
    Genprex, Inc. (NASDAQ: GNPX) rose 20.23 percent to close at $10.58.
    Turtle Beach Corporation (NASDAQ: HEAR) shares gained 17.62 percent to close at $17.82.
    Aptevo Therapeutics Inc. (NASDAQ: APVO) rose 17.1 percent to close at $5.82.
    Phoenix New Media Limited (NYSE: FENG) shares jumped 16.23 percent to close at $4.87 following Q1 earnings.
    Stein Mart, Inc. (NASDAQ: SMRT) rose 16.04 percent to close at $3.69.
    PPDAI Group Inc. (NASDAQ: PPDF) climbed 15.99 percent to close at $7.98 following Q1 results.
    Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.93 percent to close at $3.42.
    LiqTech International, Inc. (NASDAQ: LIQT) gained 15.59 percent to close at $0.5532 following Q1 results.
    Sophiris Bio, Inc. (NASDAQ: SPHS) gained 13.92 percent to close at $3.52 on Tuesday following Q1 results.
    Euroseas Ltd. (NASDAQ: ESEA) jumped 13.4 percent to close at $2.37.
    Iteris, Inc. (NASDAQ: ITI) shares surged 13.05 percent to close
  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares rose 14.1 percent to $3.65 in the pre-market trading session after reporting 2017 year-end results.
    LightPath Technologies, Inc. (NASDAQ: LPTH) rose 13.3 percent to $2.43 in pre-market trading after reporting a third-quarter earnings beat.
    MYnd Analytics, Inc. (NASDAQ: MYND) rose 10.5 percent to $3.49 in pre-market trading. MYnd Analytics reported a Q2 net loss of $2.7 million on revenue of $459,900.
    SORL Auto Parts, Inc. (NASDAQ: SORL) shares rose 8.4 percent to $5.68 in pre-market trading after reporting upbeat Q1 results.
    Famous Dave's of America, Inc. (NASDAQ: DAVE) shares rose 7.7 percent to $8.40 in pre-market trading after the company reported upbeat earnings for its first quarter on Monday.
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 7.5 percent to $6.45 in pre-market trading after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data.
    Mimecast Ltd (NASDAQ: MIME) rose 6.5 percent to $43.50 in pre-market trading following a first-quarter sales beat.
    Boxlight Corporation (NASDAQ: BOXL) rose 6 percent to $12.50 in pre-market trading after surging 77.44 percent on Monday.
    Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares rose 6 percent to $26.05 in pre-market trading after climbing 3.58 percent on Monday.
    PPDAI Group Inc. (NASDAQ: PPDF) rose 4.7 percent to $7.20 in pre-market trading following Q1 results.
    Xunlei Limited (NASDAQ: XNET) rose 4.1 percent to $13.88 in pre-market trading after gaining 2.54 percent on Monday.
    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) shares rose 4.5 percent to $21.73 in pre-market trading. Mizuho upgraded Valeant from Neutral to Buy.
    Bovie Medical Corporation (NYSE: BVX) rose 4.1 percent to $3.80 in pre-market trading after reporting a first-quarter sales beat.
    Myomo, Inc. (NYSE: MYO) rose 3.4 percent to $4.00 in pre-market trading after jumping 23.25 percent o
  • [By Lisa Levin]

    Shares of SORL Auto Parts, Inc. (NASDAQ: SORL) got a boost, shooting up 13 percent to $5.90 after reporting upbeat Q1 results.

    Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) shares were also up, gaining 24 percent to $27.3947 following Q3 results.

  • [By Lisa Levin]

    SORL Auto Parts, Inc. (NASDAQ: SORL) is expected to report quarterly earnings at $0.19 per share on revenue of $86.96 million.

    Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is projected to report quarterly loss at $0.39 per share.

Top 5 Medical Stocks To Watch For 2018: Papa Murphy's Holdings, Inc.(FRSH)

Advisors’ Opinion:

  • [By Shane Hupp]

    Papa Murphy’s Holdings, Inc. (NASDAQ:FRSH) – Investment analysts at Jefferies Group decreased their Q3 2018 earnings per share (EPS) estimates for shares of Papa Murphy’s in a report issued on Wednesday, May 9th. Jefferies Group analyst A. Barish now expects that the company will post earnings per share of ($0.01) for the quarter, down from their previous forecast of $0.04. Jefferies Group also issued estimates for Papa Murphy’s’ Q4 2018 earnings at $0.15 EPS and FY2019 earnings at $0.39 EPS.

  • [By Stephan Byrd]

    Wall Street brokerages expect Papa Murphy’s Holdings, Inc. (NASDAQ:FRSH) to post $28.61 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Papa Murphy’s’ earnings, with estimates ranging from $28.46 million to $28.75 million. Papa Murphy’s posted sales of $31.99 million in the same quarter last year, which would indicate a negative year over year growth rate of 10.6%. The company is expected to report its next earnings report after the market closes on Wednesday, May 9th.

Top 5 Medical Stocks To Watch For 2018: Marcus Corporation (MCS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    AMC Entertainment (NYSE: AMC) and Marcus (NYSE:MCS) are both consumer discretionary companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

  • [By Joseph Griffin]

    Marcus (NYSE: MCS) and AMC Entertainment (NYSE:AMC) are both consumer discretionary companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership.

  • [By Max Byerly]

    In other news, VP Thomas F. Kissinger sold 10,000 shares of Marcus stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $29.12, for a total value of $291,200.00. Following the transaction, the vice president now owns 81,664 shares in the company, valued at $2,378,055.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Diane M. Gershowitz sold 12,750 shares of the firm’s stock in a transaction dated Friday, April 6th. The stock was sold at an average price of $30.86, for a total value of $393,465.00. Following the completion of the sale, the director now directly owns 7,482 shares in the company, valued at $230,894.52. The disclosure for this sale can be found here. Insiders have sold 44,250 shares of company stock valued at $1,343,255 in the last three months. 32.88% of the stock is owned by corporate insiders.

    ILLEGAL ACTIVITY WARNING: “Barrington Research Brokers Lower Earnings Estimates for Marcus Co. (MCS)” was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3367299/barrington-research-brokers-lower-earnings-estimates-for-marcus-co-mcs.html.

    Marcus Company Profile

Top 5 Medical Stocks To Watch For 2018: Tyson Foods Inc.(TSN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tyson Foods, Inc. (NYSE: TSN) reported weaker-than-expected results for its fiscal second quarter.

    Tyson posted quarterly earnings of $1.271 per share on sales of $9.773 billion. Analysts expected earnings of $1.32 per share on sales of $9.89 billion. Tyson expects FY18 earnings of $6.55 to $6.70 per share.

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Sysco Corporation (NYSE: SYY) to report quarterly earnings at $0.64 per share on revenue of $14.34 billion before the opening bell. Sysco shares rose 0.18 percent to close at $62.29 on Friday.
    Analysts expect Tyson Foods, Inc. (NYSE: TSN) to report quarterly earnings at $1.32 per share on revenue of $9.89 billion before the opening bell. Tyson shares rose 1.39 percent to close at $66.97 on Friday.
    International Flavors & Fragrances Inc. (NYSE: IFF) reported upbeat earnings for its first quarter and agreed to acquire Frutarom for $7.1 billion. International Flavors shares dropped 5.03 percent to $135.00 in pre-market trading.
    Before the opening bell, Louisiana-Pacific Corporation (NYSE: LPX) is projected to report quarterly earnings at $0.67 per share on revenue of $692.63 million. Louisiana-Pacific shares gained 2.09 percent to close at $28.32 on Friday.
    Analysts are expecting Willis Towers Watson Public Limited Company (NYSE: WLTW) to have earned $3.01 per share on revenue of $2.23 billion in the latest quarter. Willis Towers Watson will release earnings before the markets open. Willis Towers Watson shares gained 0.98 percent to close at $148.91 on Friday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By ]

    But what investors are overlooking are the fundamental risks to this logic. Corporate earnings are the lifeblood of the market, keep in mind. Higher oil prices have already translated into higher gas prices, which is a key risk to automakers such as Ford (F) and General Motors (GM) that have pivoted big-time to producing SUVs and trucks. Higher oil prices have already taken a toll on earnings for packaged food giants like Proctor & Gamble (PG) and Tyson Foods (TSN) . Now, each are staring at consumer price increases because it costs more to deliver their products to stores.

Top 10 Warren Buffett Stocks To Buy Right Now

Is volatilityfinally back! You bet your assets it is. The Dow fell well over 600 points into the closing bell, and the major equity indexes followed suit. As a reminder, investors have been stating openly that they wanted a big pullback so they could buy more of their favorite stocks. The only problem is that most retail investors usually freeze during sell-offs because they are scary while they are happening.

24/7 Wall St. wanted to get into some of the major index readings and market movers. First, perhaps the words of Warren Buffett should be considered during a big sell-off: be fearful when others are greedy, and be greedy when others are fearful.

Last weekend we wrote our daily email subscribers how surprising it was that the Dow Jones Industrial Average had already crossed 26,400 and the S&P 500 hit 2,855 as our official baseline targets for 2018. We warned when these were issued that our baseline targets felt too conservative, but it was still surprising. Then the market selling began shortly thereafter.

Top 10 Warren Buffett Stocks To Buy Right Now: Portola Pharmaceuticals, Inc.(PTLA)

Advisors’ Opinion:

  • [By Logan Wallace]

    Portola Pharmaceuticals (NASDAQ:PTLA) has been given a $80.00 target price by equities research analysts at Oppenheimer in a research note issued to investors on Sunday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target points to a potential upside of 88.50% from the stock’s previous close.

  • [By Lisa Levin]

    Shares of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) got a boost, shooting up 21 percent to $40.90 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban.

  • [By Motley Fool Staff]

    Portola Pharmaceuticals (NASDAQ:PTLA) could win approvals from the Food and Drug Administration for two important new drugs in the coming year. Its drug betrixaban could become the first of a new class of drugs to be green-lighted for reducing the chance of blood clots forming in acute medically ill patients, and its AndexXa could become the first antidote approved to reverse the effects of top-selling anticoagulants that are already billion-dollar blockbusters.

Top 10 Warren Buffett Stocks To Buy Right Now: AxoGen, Inc.(AXGN)

Advisors’ Opinion:

  • [By Shane Hupp]

    AxoGen, Inc (NASDAQ:AXGN) – Analysts at William Blair raised their Q2 2018 earnings estimates for AxoGen in a research report issued on Monday, May 14th. William Blair analyst K. Krum now expects that the medical equipment provider will post earnings per share of ($0.04) for the quarter, up from their prior forecast of ($0.05). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for AxoGen’s Q4 2018 earnings at ($0.03) EPS and FY2018 earnings at ($0.25) EPS.

Top 10 Warren Buffett Stocks To Buy Right Now: Grupo Aeroportuario Del Pacifico, S.A. de C.V.(PAC)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Right now, it’s time for that yearly review of the ones he picked to honor the month, and also the briefly famous pregnant giraffe: five companies, and the first letters of their tickers spelled out A-P-R-I-L. They were Axon Enterprise(NASDAQ:AAXN), Grupo Aeroportuario del Pacific(NYSE:PAC), ResMed(NYSE:RMD), Intuitive Surgical (NASDAQ:ISRG), and Live Nation(NYSE:LYV).

Top 10 Warren Buffett Stocks To Buy Right Now: Continental Resources, Inc.(CLR)

Advisors’ Opinion:

  • [By Shane Hupp]

    Clearwater Seafoods (TSE:CLR) declared a quarterly dividend on Tuesday, May 8th, Zacks reports. Shareholders of record on Saturday, May 19th will be given a dividend of 0.05 per share on Friday, June 1st. This represents a $0.20 dividend on an annualized basis and a yield of 3.96%. The ex-dividend date of this dividend is Thursday, May 17th.

  • [By Logan Wallace]

    Clearwater Seafoods (TSE:CLR) Director Richard Lawrence Gillis Hood sold 6,200 shares of the firm’s stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of C$4.90, for a total value of C$30,380.00.

Top 10 Warren Buffett Stocks To Buy Right Now: Natural Grocers by Vitamin Cottage, Inc.(NGVC)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares rose 35.8 percent to $3.00.
    Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares surged 32 percent to $8.94 after reporting upbeat Q1 earnings.
    Carbon Black, Inc. (NASDAQ: CBLK) gained 29.6 percent to $24.62. Carbon Black priced its IPO at $19 per share.
    California Resources Corporation (NYSE: CRC) shares rose 26.8 percent to $32.70 following upbeat Q1 earnings.
    Pandora Media, Inc. (NYSE: P) gained 25 percent to $7.185 after reporting strong quarterly results.
    Medifast, Inc. (NYSE: MED) shares climbed 23.7 percent to $122.87 after the company reported strong Q1 results and raised its FY18 guidance.
    Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.2 percent to $8.4999 after reporting Q2 results.
    Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) gained 22.2 percent to $41.27 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban.
    Shake Shack Inc (NYSE: SHAK) rose 22.2 percent to $57.955 after the company reported upbeat results for its first quarter and raised its FY18 guidance.
    Atomera Incorporated (NASDAQ: ATOM) jumped 19.7 percent to $6.12 after reporting Q1 results.
    Super Micro Computer, Inc. (NASDAQ: SMCI) rose 16.4 percent to $21.00 after reporting strong preliminary results for the third quarter.
    Titan International, Inc. (NYSE: TWI) shares rose 16.4 percent to $12.21 following Q1 earnings.
    Integer Holdings Corporation (NYSE: ITGR) shares gained 14.9 percent to $63.75 following Q1 results.
    Control4 Corporation (NASDAQ: CTRL) shares climbed 14.5 percent to $23.98 folloiwng strong Q1 results.
    B&G Foods, Inc. (NYSE: BGS) climbed 12.6 percent to $25.40 after reporting Q1 earnings.
    HMS Holdings Corp (NASDAQ: HMSY) shares gained 10 percent to $19.59 after reporting upbeat quarterly earnings.
    Viavi Solutions Inc. (NASDAQ: VIAV) rose 7 percent to $10.09 following Q3 r
  • [By Lisa Levin] Gainers
    Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares jumped 29.86 percent to close at $2.87 on Friday.
    Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares gained 28.87 percent to close at $8.75 after reporting upbeat Q1 earnings.
    Mexco Energy Corporation (NYSE: MXC) gained 27.02 percent to close at $5.4744.
    Carbon Black, Inc. (NASDAQ: CBLK) climbed 26 percent to close at $23.94. Carbon Black priced its IPO at $19 per share.
    Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) rose 25.64 percent to close at $42.44 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban.
    Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.19 percent to close at $8.50 after reporting Q2 results.
    California Resources Corporation (NYSE: CRC) shares gained 22.45 percent to close at $31.58 following upbeat Q1 earnings.
    Atomera Incorporated (NASDAQ: ATOM) gained 22.31 percent to close at $6.25 after reporting Q1 results.
    Medifast, Inc. (NYSE: MED) shares jumped 22.27 percent to close at $121.46 after the company reported strong Q1 results and raised its FY18 guidance.
    Jerash Holdings (US), Inc. (NASDAQ: JRSH) gained 20.86 percent to close at $8.46.
    Pandora Media, Inc. (NYSE: P) rose 19.83 percent to close at $6.89 after reporting strong quarterly results.
    Shake Shack Inc (NYSE: SHAK) rose 18.01 percent to close at $55.95 on Friday after the company reported upbeat results for its first quarter and raised its FY18 guidance.
    Super Micro Computer, Inc. (NASDAQ: SMCI) rose 17.73 percent to close at $21.25 after reporting strong preliminary results for the third quarter.
    Schmitt Industries, Inc. (NASDAQ: SMIT) rose 17.41 percent to close at $2.36.
    Titan International, Inc. (NYSE: TWI) shares gained 16.78 percent to close at $12.25 following Q1 earnings.
    Integer Holdings Corporation (NYSE: ITGR) shares rose 14.23 percent to close at $63.40 following Q1 result

Top 10 Warren Buffett Stocks To Buy Right Now: National Western Life Group, Inc.(NWLI)

Advisors’ Opinion:

  • [By Logan Wallace]

    National Western Life (NASDAQ: NWLI) and Brighthouse Financial (NASDAQ:BHF) are both finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Top 10 Warren Buffett Stocks To Buy Right Now: GRAVITY Co. Ltd.(GRVY)

Advisors’ Opinion:

  • [By Cooper Creagan]

    For example, if you had taken five minutes to set up a Night Trade on Gravity Co. (Nasdaq: GRVY) in October, you could’ve tripled your money, and then some.

  • [By Max Byerly]

    ILLEGAL ACTIVITY WARNING: “Gravity (GRVY) Receives Coverage Optimism Score of 0.17” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3382037/gravity-grvy-receives-coverage-optimism-score-of-0-17.html.

Top 10 Warren Buffett Stocks To Buy Right Now: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Paul Ausick]

    The Dow stock posting the largest daily percentage loss ahead of the close Thursday was Cisco Systems Inc. (NASDAQ: CELG) which traded down 3.69% at $43.50. The stock’s 52-week range is $30.36 to $46.37. Volume was about 60% above the daily average of around 25 million shares. The company reported earnings after markets closed last night that were less grand than investors had hoped for.

  • [By Keith Speights]

    Celgene (NASDAQ:CELG) is co-developing Bluebird’s lead CAR-T therapy, bb2121. The CAR-T immunotherapya customized lentiviral vector to modify T cells so the T cells can recognize targeted proteins on the surface of cancer cells and attack them. Celgene plans to advance bb2121 to a phase 3 clinical study as a third-line treatment for multiple myeloma.

  • [By Todd Campbell, Leo Sun, and Daniel Miller]

    Sometimes, earnings grow faster than stock prices. And other times,growth stocks go on sale even though revenue is still climbing. In both cases, P/E ratios can fall to levels that make growth stocks look more like value stocks. When that happens, buying shares can lead to market-beating returns, so we asked these three Motley Fool investors if there are any growth stocks on their radar that are value-priced. They responded by recommendingCelgene Corp. (NASDAQ:CELG), Goodyear Tire & Rubber (NASDAQ:GT), and Apple Inc. (NASDAQ:AAPL). Are these growth-stock bargains worth adding to your portfoio?

  • [By Paul Ausick]

    Celgene Corp. (NASDAQ: CELG) dropped about 2.7% Thursday to post a new 52-week low of $79.16. Shares closed at $81.36 on Wednesday and the stock’s 52-week high is $147.17. Volume of around 7.4 million shares was about 5% above the daily average. The company was one of several named in an FDA report of drugmakers who may be illegally blocking access to delay cheaper generic copies.

Top 10 Warren Buffett Stocks To Buy Right Now: Fidelity Southern Corporation(LION)

Advisors’ Opinion:

  • [By Max Byerly]

    ValuEngine cut shares of Fidelity Southern (NASDAQ:LION) from a strong-buy rating to a buy rating in a research note published on Wednesday morning.

Top 10 Warren Buffett Stocks To Buy Right Now: BGC Partners, Inc.(BGCP)

Advisors’ Opinion:

  • [By Logan Wallace]

    LPL Financial (NASDAQ: LPLA) and BGC Partners (NASDAQ:BGCP) are both mid-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

  • [By ]

    Cramer was bearish on BGC Partners (BGCP) , Dr Pepper Snapple (DPS) , Sterling Construction Co. Inc.  (STRL) and B&G Foods (BGS) .

    Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

  • [By ]

    BGC Partners (BGCP) : “We’re in a market where Goldman Sachs (GS) got slammed. I’m going with them.”

    Ecolab (ECL) : “That’s a terrific situation that I want you to buy more of if it comes down.”

Traders Sell Celgene (CELG) on Strength (CELG)

Investors sold shares of Celgene (NASDAQ:CELG) on strength during trading hours on Friday. $125.14 million flowed into the stock on the tick-up and $200.18 million flowed out of the stock on the tick-down, for a money net flow of $75.04 million out of the stock. Of all stocks tracked, Celgene had the 12th highest net out-flow for the day. Celgene traded up $2.16 for the day and closed at $84.54

CELG has been the subject of several analyst reports. Mizuho set a $128.00 target price on shares of Celgene and gave the company a “buy” rating in a research note on Wednesday, January 17th. Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the company a “hold” rating in a research note on Wednesday, January 17th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $114.80 target price for the company in a research note on Wednesday, January 17th. Piper Jaffray reissued a “hold” rating and issued a $104.00 target price on shares of Celgene in a research note on Thursday, January 18th. Finally, BidaskClub cut shares of Celgene from a “hold” rating to a “sell” rating in a research note on Saturday, January 20th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. Celgene has a consensus rating of “Buy” and a consensus target price of $123.98.

Get Celgene alerts:

The stock has a market cap of $60.02 billion, a PE ratio of 12.36, a PEG ratio of 0.56 and a beta of 1.49. The company has a debt-to-equity ratio of 3.92, a quick ratio of 4.80 and a current ratio of 2.53.

Celgene (NASDAQ:CELG) last announced its earnings results on Friday, May 4th. The biopharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.96 by $0.09. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.47 billion. Celgene had a net margin of 20.73% and a return on equity of 72.92%. Celgene’s quarterly revenue was up 19.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.68 earnings per share. equities analysts anticipate that Celgene will post 7.63 earnings per share for the current fiscal year.

Celgene announced that its Board of Directors has initiated a share buyback plan on Wednesday, February 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

In related news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $95.99, for a total value of $887,907.50. Following the completion of the transaction, the director now owns 94,801 shares of the company’s stock, valued at $9,099,947.99. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ernest Mario sold 13,370 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $94.49, for a total value of $1,263,331.30. The disclosure for this sale can be found here. In the last three months, insiders sold 41,120 shares of company stock valued at $3,879,509. 0.95% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. Virtue Capital Management LLC acquired a new position in Celgene in the fourth quarter valued at about $101,000. Robecosam AG acquired a new position in Celgene during the third quarter worth about $114,000. American Beacon Advisors Inc. acquired a new position in Celgene during the fourth quarter worth about $120,000. Capital Bank & Trust Co raised its stake in Celgene by 166.8% during the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 517 shares in the last quarter. Finally, Truewealth LLC acquired a new position in Celgene during the fourth quarter worth about $123,000. 81.13% of the stock is owned by institutional investors and hedge funds.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Better Buy: Ziopharm Oncology, Inc. vs. bluebird bio Inc.

Chimeric antigen receptor T-cell (CAR-T) therapies and gene therapies are hot commodities these days. But some small biotechs developing CAR-T drugs and gene therapies are hotter than others.

Over the last 12 months, bluebird bio (NASDAQ:BLUE) stock has more than doubled. During the same period, Ziopharm Oncology’s (NASDAQ:ZIOP) share price has tumbled over 30%. That’s the past, though. Which of these two clinical-stage biotech stocks is the better pick for investors now?

Cancer cell and DNA strand

Image source: Getty Images.

The case for Ziopharm

The best argument for buying Ziopharm stock right now is the biotech’s awkwardly named lead candidate,Ad-RTS-hIL-12. The gene-therapy product is anadenoviral vector — a genetically engineered adenovirus designed to insert a gene into a cell. Ad-RTS-hIL-12 is administered through an injection into a tumor to cause a controlled expression of IL-12, a cell-signaling molecule that helps the immune system attack tumors.

Ziopharm hoped to initiate a pivotal phase 3 clinical study in the second half of 2018 evaluating Ad-RTS-hIL-12 in combination with small-molecule activator ligandveledimexin treating recurrent glioblastoma multiforme (rGBM), an aggressive form of brain cancer. However, the company announced on Thursday that it put those plans on hold while it resolves some technical manufacturing issues.

The gene therapy is a promising one. Ad-RTS-hIL-12 produced positive results in earlier clinical studies. In particular, Ziopharm reported that its lead candidate turned cold tumors hot. With hot tumors, the immune system remains engaged in attacking cancer cells even after a tumor is removed. That’s not the case with cold tumors.

The biotech is also evaluating Ad-RTS-hIL-12 in phase 1 clinical studies targeting treatment of brain cancer. One of those studies combines Bristol-Myers Squibb’s checkpoint inhibitor Opdivo with Ziopharma’s gene therapy in treating rGBM. Another includes Ad-RTS-hIL-12 in combination with veledimexin treating brain tumors in pediatric patients.

Ziopharm is partnering with Intrexon, Merck KGaA, and MD Anderson Cancer Center on CAR-T and T-cell receptor (TCR) programs. Patient enrollment is in progress on a phase 1 study of one CAR-T therapy in treating acute myeloid leukemia (AML). The company expects two other phase 1 studies, one for a CAR-T therapy and the other for a TCR therapy, to begin in the second half of this year.

That early-stage CAR-T clinical trial should be ofparticular interest to investors. It will be Ziopharm’s first clinical study evaluating a CAR-T that can be manufactured at the point of care. If successful, it holds the promise to significantly reduce the complexity and cost associated with current approved CAR-T therapies.

The case for Bluebird

Like Ziopharm, Bluebird is developing CAR-T programs, but its lead candidates are gene therapies. The biotech’s most advanced product is LentiGlobin.The product works by inserting a functional human beta-globin gene into a patient’s own hematopoietic stem cells (undifferentiated cells that develop into various types of blood cells) outside the body. These modified stem cells are then transplanted into the patient’s bloodstream through infusion.

Bluebird plans to submit LentiGlobin for approval in Europe in the second half of 2018 for treating patients with transfusion-dependent beta-thalassemia, a rare genetic blood disorder. The company is also evaluating LentiGlobin in a phase 1 study targeting treatment of severe sickle cell disease.

Lenti-D is another gene therapy in Bluebird’s pipeline. Similar to LentiGlobin, Lenti-D involves insertion of a gene into a patient’s stem cells and the transplanting of those stem cells back into the patient’s bloodstream. Lenti-D, though, inserts afunctioning copy of the ABCD1 gene and targets treatment of cerebral adrenoleukodystrophy (CALD), a rare genetic metabolic disorder. Bluebird is evaluating Lenti-D in a phase 1/2 study and plans to present results from the study later this year.

Celgene (NASDAQ:CELG) is co-developing Bluebird’s lead CAR-T therapy, bb2121. The CAR-T immunotherapya customized lentiviral vector to modify T cells so the T cells can recognize targeted proteins on the surface of cancer cells and attack them. Celgene plans to advance bb2121 to a phase 3 clinical study as a third-line treatment for multiple myeloma.

Better buy

Both of these biotechs have promising pipelines. But I think Bluebird is the better buy right now for three key reasons.

First, Bluebird is closer to potentially having a product on the market than Ziopharm is. If all goes well, Bluebird could launch LentiGlobin next year. It’s uncertain when Ziopharm’s pivotal study forAd-RTS-hIL-12 will begin.

Second, I really like that Celgene has partnered with Bluebird. In March, the big biotech exercised its option to co-market bb2121 in the U.S. and exclusively market the CAR-T therapy outside of the U.S. That’s a great stamp of approval from a major player in the industry.

Third, Bluebird is in better shape financially. In its first-quarter results, the biotech reported a cash stockpile of $1.57 billion. By comparison, Ziopharm had $51.1 million in cash and cash equivalents on hand at the end of the first quarter.

The biggest knock against Bluebird is that its market cap of nearly $9 billion already reflects high hopes for its pipeline. There are risks that the biotech’s products could stumble in clinical trials or the regulatory approval process. Still, I think Bluebird’s chances look pretty good. It’s not the kind of stock you’d want to bet the farm on, because of the inherent risks with a clinical-stage biotech, but buying a small stake could pay off in a big way.

3 Growth Stocks at Deep-Value Prices

Sometimes, earnings grow faster than stock prices. And other times,growth stocks go on sale even though revenue is still climbing. In both cases, P/E ratios can fall to levels that make growth stocks look more like value stocks. When that happens, buying shares can lead to market-beating returns, so we asked these three Motley Fool investors if there are any growth stocks on their radar that are value-priced. They responded by recommendingCelgene Corp. (NASDAQ:CELG), Goodyear Tire & Rubber (NASDAQ:GT), and Apple Inc. (NASDAQ:AAPL). Are these growth-stock bargains worth adding to your portfoio?

A top growth stock that’s in the bargain bin

Todd Campbell (Celgene): Growth at bargain-basement prices is a bit of an oxymoron because value stocks usually aren’t double-digit growers. That’s not the case for Celgene, though.

A light bulb illuminated above a person's head in front of a blackboard covered by diagrams.

Image source: Getty Images.

Even though Celgene reported 20% year-over-year sales growth last quarter, its shares are trading at a forward P/E ratio of only 8.1. That’s a cut-rate valuation for a company that expects to deliver sales of at least $19 billion in 2020, up from $13 billion in 2017.

The low valuation is a result of a big setback Celgene suffered on a lead drug candidate in its pipeline, ozanimod. Celgene had filed for FDA approval of ozanimod for multiple sclerosis, a mega-blockbuster indication, but the FDA rejected the application, and that pushes out the timeline for a potential green light.

Celgene says it will refile for approval early in 2019, and if so, then ozanimod could begin chipping away at sales in the indication in 2020. Until then, there’s plenty going on at the company that could spark a rally in its share price again.

For instance, the company recently acquired Juno Therapeutics to get its hands on a pipeline of chimeric antigen receptor T-cell gene therapies (CAR-Ts). CAR-Ts represent one of the biggest recent advances in treating blood cancer, and depending on trial results, the first CAR-T from this collaboration could be filed for approval next year. Similarly, Celgene is partnering with bluebird bio (NASDAQ:BLUE) on bb2121, a CAR-T for multiple myeloma. So far, bb2121 is delivering 90%-plus response rates in heavily pre-treated patients, and if that success continues, it could end up on regulators’ desk for approval next year, too.

In 2018, Celgene thinks sales will be $14.8 billion, and that adjusted EPS will be $8.45. In 2017, sales and EPS were $13 billion and $7.44, respectively, so the guidance reflects a company that’s far from struggling. Given the sell-off and the potential for sales to climb significantly through 2020, buying Celgene’s shares could be smart.

Driverless cars need tires, too

Daniel Miller (Goodyear Tire & Rubber):You’ve likely heard new-vehicle sales in the U.S. are currently plateauing, which makes it difficult to sell a near-term growth story for automakers. Nonetheless, the auto industry has trends that could provide strong growth for Goodyear despite the company’sbeing sold off with the rest of the industry — it currently trades at a paltry forward P/E of 6.6, per Morningstar estimates.

Total sales are plateauing, but the sales mix is wildly shifting in favor of larger vehicles such as SUVs, crossovers, and pickup trucks. That means more larger tires on the road, and that means better margins for Goodyear. In 2009, light trucks were 45% of the U.S. new vehicle market; that exploded in the years since to 68% during the first quarter of 2018. Further, LMC Automotive predicts light trucks will generate roughly 73% of the market as soon as 2022.

A sales mix in the Americas with such a large percentage of light trucks is one growth catalyst for Goodyear, but there’s a long-term catalyst as well: driverless vehicles. Consider that by 2030, 25% of global miles traveled will be shared, according to The Boston Consulting Group, and the autonomous market will be a $7 trillion business by 2050, according to an Intel report. As the market shifts to fleet ownership, rather than individual consumers, Goodyear could leverage its physical-store tire services to sign partnerships with fleet owners, which could become a lucrative business.

Granted, the driverless-car future is an uncertain one, but one thing is certain: Tires, and other products associated with driverless cars, will become much more complex. That means growth — long-term growth — for Goodyear if it can leverage its distribution network, innovative tires, and service bays to carve out its place in the market.

Hidden in plain sight

Leo Sun (Apple): Some investors claim that Apple’s high-growth days are over. Yet the tech giant posted accelerating double-digit sales growth over the past three quarters, and analysts expect its revenue to rise 14% this year. Apple’s earnings are also expected to climb 24% this year.

Those are remarkable growth figures for a stock that trades at less than 16 times this year’s earnings. Moreover, Apple pays a forward dividend yield of 1.4%, and it has hiked that payout annually for five straight years. It also recently announced a new $100 billion buyback — which is enough to repurchase over 10% of its outstanding shares at current prices.

Apple still depends heavily on the iPhone, which generated 62% of its sales last quarter. But its services revenue — from Apple Pay, Apple Music, iTunes, its App Store, and other services — also jumped 31% annually during the quarter and accounted for 15% of its top line. Apple also stated that its paid subscriber base grew by 100 millionin the last year to 270 million.

Millennials sitting on a floor using their smartphones and tablets.

Image source: Getty Images.

That massive user base gives Apple the foundation to launch a wide variety of new services for adjacent markets — like streaming video, online news, and healthcare — to lock in users and reduce its dependence on hardware sales. That’s an advantage none of its smartphone rivals can match.

As I’ve said before, investors should think of Apple as a consumer goods company instead of a tech one. By comparing Apple’s valuations to other consumer goods companies, it’s easy to see how undervalued this stellar growth stock is.

bluebird bio Looks for Data Ahead

bluebird bio (NASDAQ:BLUE) reportedfirst-quarter earnings last week, but like the biotech typically does, management didn’t hold a conference call, which makes the earnings release more of a rehash of the quarter than an actual update.

Bluebird results: The only number that really matters

Metric

Q1 2018

Q4 2017

Quarter-Over-Quarter Change

Cash, cash equivalents and marketable securities

$1.57 billion

$1.61 billion

($48 million)

Data source: Bluebird.

What happened with Bluebird this quarter?
Without any drugs on the market, revenue and earnings aren’t particularly important for Bluebird. For the record, the company lost $115 million in the first quarter on a GAAP basis. The cash situation is arguably more important. While the change in its nest egg looks like Bluebird is being extremely frugal, the biotech actually receivedan additional $48.6 million in the first quarter from its secondary offering, negating some of the cash burn. The original Northstar (HGB-204) phase 1/2 trial completed two years of follow-up, allowing Bluebird to submit its marketing application for LentiGlobin in Europe later this year. Given the solid data for bb2121, its anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T cell (CAR T) therapy, Bluebird elected to co-develop the treatment with its partner Celgene (NASDAQ:CELG).
Doctor comforting a patient

Image source: Getty Images.

What management had to say

Nick Leschly, who goes by the title of chief Bluebird, said, “Our plans remain on track for our first regulatory filing inEuropefor [transfusion dependent beta-thalassemia], we are rapidly advancing development of bb2121 for patients, and we are focused on future innovation platforms.”

Looking forward

Investors should get some data for LentiGlobin in transfusion-dependent beta-thalassemia (TDT) patients at the European Hematology Association meeting, and for bb2121at the American Society of Clinical Oncology meeting — both of which occur next month. But as is typical for Bluebird, the big medical meeting for data will be for the American Society of Hematology (ASH), which isn’t until December. At ASH, investors can expect data for LentiGlobin in TDT and sickle cell disease as well as data for its follow-on CAR-T therapy bb21217.

This year, management also plans to lay out its plan to get LentiGlobin approved for sickle cell disease.

Best Dividend Stocks To Buy For 2019

Target Corporation (TGT) offers a perfect buying opportunity to long-term investors, as the company continues to generate optimistic results, while strong operational and timely business strategies will allow it to outperform the market headwinds. Retailers have experienced significant losses in the first half this year due to rising inflation, increasing costs, mounting competition and tightening economy, resulting in a YTD decline of 21% in retail stock.

Although Targets share price declined sharply 29% since the start of this year amid an unstable market environment in retail industry, the drop offers a compelling buying opportunity, in my opinion, despite the unstable market environment.

Retailers have been experiencing significant headwinds over the last couple of years as the market dynamic for retailers has started changing after technological innovations and a massive growth in private labels. In addition, strong market competition and rising costs are creating pressure on retailers’ margins and earnings potential, further impacting their cash generation and the dividend growth potential.

Best Dividend Stocks To Buy For 2019: BP Prudhoe Bay Royalty Trust(BPT)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, energy shares fell by 1.30 percent. Meanwhile, top losers in the sector included BP Prudhoe Bay Royalty Trust (NYSE: BPT), down 14 percent, and Gulf Island Fabrication, Inc. (NASDAQ: GIFI), down 13 percent.

  • [By WWW.MONEYSHOW.COM]

    Our featured recommendation, the BP Prudhoe Bay Royalty Trust (BPT), is a grantor trust. What that means is that the trust holds royalty interest in minerals from the Prudhoe Bay on the North Slope of Alaska.

Best Dividend Stocks To Buy For 2019: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Todd Campbell]

    A new and highly anticipated study byCelgene Corp. (NASDAQ:CELG) shows that its promising multiple sclerosis drug could soon reshape the $19 billion multiple sclerosis market. On Friday, management reported that ozanimod met its primary endpoint for reducing MS relapses better than Biogen Inc.’s (NASDAQ:BIIB) Avonex, and importantly, it did so without any new safety risks.

  • [By Keith Speights]

    Celgene (NASDAQ:CELG) has certainly had its challenges over the last year, but you wouldn’t have known it from the company’s first-quarter results. The big biotech announced on Friday that its Q1 revenue jumped 20% year over year, with adjusted diluted earnings per share soaring 23%.

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

Best Dividend Stocks To Buy For 2019: Rennova Health, Inc.(RNVA)

Advisors’ Opinion:

  • [By Ashley Moore]

    Here is a list of the top 10 best small-cap stocks based on price gains per share so far in 2017:

    Company (Ticker)Price per Share% Change AquaBounty Technologies Inc. (Nasdaq: AQB)$14.338,646.99%Rennova Health Inc. (Nasdaq: RNVA)$3.133,333.73%China Gengsheng Minerals Inc. (OTCMKTS: CHGS)$0.021,718.18%Sunshine Heart Inc. (Nasdaq: SSH)$3.851,071.43%CTI BioPharma Corp. (Nasdaq: CTIC)$4.30991.76%Catalyst Biosciences Inc. (Nasdaq: CBIO)$6.22853.85%TearLab Corp. (Nasdaq: TEAR)$4.20707.85%Pulmatrix Inc. (Nasdaq: PULM)$3.86566.10%Real Goods Solar Inc. (Nasdaq: RGSE)$1.43498.75%Calithera Biosciences Inc. (Nasdaq: CALA)$11.70281.54%

Are These 2 Biotech Laggards Ready to Rebound?

Biotech hasn’t been a great place to invest your money in 2018.The iShares Nasdaq Biotechnology Index, after all, is down by over 4% at present, and summer has historically been a down time for this high-risk space. So, there’s little reason to believe a widespread rally is coming anytime soon.

Even against this dour backdrop, however, several former top biotech stocks have turned out to be particularly disappointing investing vehicles this year. Acadia Pharmaceuticals (NASDAQ:ACAD) and Celgene Corporation (NASDAQ:CELG), for instance, are both trading near their 52-week lows right now. That’s a surprising turn of events given that Acadia and Celgene were two of the absolute best-performing growth stocks since about the start of 2010.

Man in a business suit facing a wall with several white arrows pointing one direction and a single yellow arrow pointing in the opposite direction.

Image source: Getty Images.

Should investors take advantage of this weakness in these two former highfliers? Let’s dig deeper to find out.

Is Acadia’s risk overstated?

Acadia stock has suffered from two interrelated issues this year. First off, the company’s valuation at the start of the year seemed to reflect an unwarranted optimism surrounding the commercial potential of Nuplazid, Acadia’s FDA-approved drug for Parkinson’s disease psychosis (PDP).

In short, investors were clearly expecting Nuplazid to achieve blockbuster status almost right out of the gate. As the drug has a questionable risk-to-reward ratio, however, it’s not all that surprising that Nuplazid has so far failed to live up to these lofty expectations.

And the drug’s murky risk-to=reward ratio is at the heart of the company’s second major issue. A recent report by CNN suggested that Nuplazid’s substantial risks outweigh its modest rewards, which, in turn, caused the FDA to take a deeper look at the drug’s emerging safety profile since coming on the market.

Although the FDA is unlikely to pull Nuplazid for a variety of reasons, investors are still concerned about this existential threat. Nuplazid, after all, is Acadia’s only product, and it doesn’t have much of a clinical pipeline to fall back on.

On the bright side, Acadia’s management has stuck by its annual 2018 sales guidance for Nuplazid of between $255 million and $270 million, and the company has been adamant about its position that this drug is an important new treatment option for PDP.

The core problem here, though, is that Acadia’s valuation is still way out of line with its peers — even after this year’s downward move. At present, Acadia’s shares are trading at a forward price-to-sales ratio of 7.9 at the high end of its estimated revenue guidance. The historical average for biotechs with traditional small-molecule drugs like Nuplazid, by contrast, is closer to 6.

With a possible black swan event lurking in the shadows (Nuplazid getting pulled from the market), it’s hard to justify buying this stock right now. At best, Acadia’s shares are now only slightly overvalued, and a buyout scenario appears to be moot issue with Nuplazid’s current regulatory risk.

Can Celgene overcome these missteps?

Celgene stock has plunged this year due to the unexpected regulatory setback for its multiple sclerosis drug candidate ozanimod, as well as the questionable acquisitions of Impact Biomedicines and Juno Therapeutics that cut deeply into the biotech’s cash reserves. The long and short of it is that Celgene is under immense pressure to find an heir apparent to its flagship multiple myeloma drug Revlimid.

Now, ozanimod was supposed to be that drug, given its potential to generate upwards of $6 billion in peak sales. With the drug’s commercial launch delayed by at least a year, however, ozanimod could end facing a far tougher competitive landscape by the time it finally hits the market.

And that’s why Celgene’s management was quick to note the sizable commercial potential of Juno’s and Impact’s lead product candidates — JCAR017 andfedratinib respectively — during itsfirst-quarter conference call last week. Unfortunately, these two product candidates do have their own set of unique problems that could significantly dampen their commercial prospects, too.

Overall, the picture that’s emerging with Celgene is a company that’s lost its way to some degree. The ozanimod fiasco triggered a change in key leadership positions, and the biotech’s acquisitions of Juno and Impact appear, in hindsight, to be questionable moves at best. Valued at a mere 8.55 times forward earnings, though, Celgene stock is probably worth the risk at these levels.

Are these two stocks worth owning right now?

Acadia could be in for some dark days in the near future. There’s no telling what the ultimate fallout from that CNN report regarding Nuplazid’s risk-to-reward ratio will be, and there’s now the remote chance that the FDA could even pull the drug from the market. As such, this speculative biotech stock arguably isn’t worth the potential headaches that could come with owning it.

Celgene, on the other hand, probably deserves the benefit of the doubt. The company has made some regrettable errors this year, but management has been proactive at dealing with them head-on.The company also has a top-notch clinical pipeline that should be able to keep the growth going for at least another five to 10 years — even if Juno and Impact both fail to live up to expectations. So with Celgene’s shares trading at rock-bottom prices from a historical perspective, investors may want to consider taking advantage and scooping up some shares.